Optimized RNA molecules
Incorporating a minimized Gnas 3' UTR sequence into RNA molecules improves manufacturability and translation efficiency, enabling effective medical applications by maintaining efficiency during nucleotide modifications and using lipid-based carriers for delivery.
Patent Information
- Application Number
- PCT/EP2025/062774
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-09
- Publication Date
- 2026-11-12
AI Technical Summary
The challenge in optimizing RNA molecules for therapeutic applications lies in identifying suitable RNA elements that enhance manufacturability and translation efficiency while allowing modification with modified nucleotides without reducing efficiency.
Incorporating a minimized 3' UTR sequence element (Gnas-min) into RNA molecules, which improves manufacturability, translation efficiency, and enables modification with nucleotides like N1-methylpseudouridine without efficiency loss, along with a lipid-based carrier for delivery.
The minimized Gnas 3' UTR sequence enhances RNA integrity, reduces dsRNA content, and maintains translation efficiency, facilitating effective medical applications such as gene therapy.
Smart Images

Figure IMGF000049_0001_TABLE 
Figure IMGF000050_0001_TABLE 
Figure IMGF000051_0001_TABLE
Abstract
Description
[0001] CU01P401WO 9th May 2025
[0002] Applicant:
[0003] CUREVAC SE
[0004] Optimized RNA molecules
[0005] Introduction:
[0006] RNA has emerged as a therapeutic molecule to treat various diseases due to its ability to direct the production of therapeutic peptides or proteins in patients. Accordingly, RNA represents a promising class of molecules for various types of diseases. However, the identification of suitable RNA elements for optimizing these molecules to further expand their therapeutic applicability remains an ongoing challenge in the field.
[0007] Therefore, one object of the present invention is to provide optimized RNA molecules suitable for medical applications. The object is solved by the subject-matter of the present invention. The inventors have identified minimized 3’ UTR sequences that, when incorporated in an RNA molecule, optimizes several important properties of the RNA molecule, including improved manufacturability, increased translation efficiency, and the ability to be modified with modified nucleotides without a reduction in translation efficiency.
[0008] Short description of the invention
[0009] The present invention is inter alia directed to an artificial RNA comprising at least one coding sequence (cds) and at least one 3’ untranslated region (3’ UTR) comprising at least one minimized Gnas 3' UTR sequence element (Gnas-min). The artificial RNA optionally comprises at least one 5’ untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element from HSD17B4. Suitably, the cds of the artificial RNA encodes a CRISPR-associated endonuclease. The artificial RNA of the invention is inter alia optimized for manufacturability, increased translation efficiency, and the ability to be modified with modified nucleotides without a reduction in translation efficiency. The invention further relates to a composition comprising at least one artificial RNA, optionally formulated in a lipid-based carrier such as an LNP. The invention further relates to the use of Gnas-min for improving the manufacturability of an RNA, the use of Gnas-min for improving translation efficiency of a modified RNA, and a method for producing the artificial RNA. Also provided are medical uses and methods of treating or preventing a disease, disorder or condition, e.g. medical uses in gene therapy. As shown in the example section (see Examples 1 to 3), the invention is inter alia based on the finding that a minimized Gnas 3’UTR sequence (Gnas-min) displays, when incorporated into an RNA molecule, several unexpected advantageous properties. Surprisingly, the expression efficiency of an RNA construct comprising a minimized Gnas 3’UTR is increased compared with a reference RNA construct comprising the fall length Gnas 3’UTR. Furthermore, minimizing the Gnas 3’UTR sequence improved the manufacturability of respective RNA constructs as e.g. the RNA integrity was improved and dsRNA content could be reduced compared to a corresponding reference RNA Moreover, the inventors found that RNA constructs comprising Gnas-min could be modified with modified nucleotides (e.g. N1- methylpseudouridine or pseudouridine) without causing a reduction of translation efficiency as, in contrast, observed for the respective reference RNA comprising the fall-length Gnas 3’UTR.
[0010] In a first aspect, the present invention provides an artificial RNA comprising at least one coding sequence and at least one 3’ untranslated region (3’ UTR) comprising at least one minimized Gnas 3’ UTR sequence element (Gnas-min).Preferably, Gnas-min consists of a section of 70 to 150 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical toSEQID NOs: 5.
[0011] Gnas-min may comprise or consist of a nucleotide sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 5-7, 53-607. Preferably Gnas-min may comprise or consist of a nucleotide sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 82-91 , more preferably SEQ ID NOs: 1-3, most preferably SEQ ID NO: 2.
[0012] Suitably, the artificial RNA comprises at least one modified nucleotide, preferably N1 -methylpseudouridine.
[0013] The artificial RNA may comprise or consist of a nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 608-610, 619-654, 662-667, or a fragment or variant of any of these sequences.
[0014] In a second aspect, the present invention provides a composition comprising the artificial RNA of the first aspect.
[0015] The at least one artificial RNA is suitably formulated in a lipid-based carrier such as a lipid nanoparticle (LNP).
[0016] In a third aspect, the present invention provides a kit or kit of parts comprising the artificial RNA of the first aspect, and / or the pharmaceutical composition of the second aspect.
[0017] In fourth and fifth aspect, the invention provides medical uses of the artificial RNA, the pharmaceutical composition, or the kit and methods of treating or preventing a disease, disorder or condition.
[0018] In a sixth aspect, the invention provides the use of Gnas-min for improving the translation efficiency of an RNA.
[0019] In a seventh aspect, the invention provides the uses of the Gnas-min for improving the manufacturability of an RNA. In an eight aspect, the invention provides a method for producing an artificial RNA.
[0020] Definitions
[0021] For the sake of clarity and readability the following definitions are provided. Any technical feature mentioned for these definitions may be read on each embodiment of the invention. Additional definitions and explanations may be specifically provided in the context of these embodiments.
[0022] About: The term “about” is used when values or determinants do not need to be identical, i.e. 100% the same and that e.g. the respective values or determinants may diverge by 1 % to 10%. Preferably, “about’ means that a value or determinant may diverge by + / -1%, +1-2%, +1-3%, +1-4%, +1-5%, + / -6%, +1-7%, +1-8%, +1-9%, + / -10%.
[0023] Derived from: The term “derived from” as used herein in the context of a nucleic acid, i.e. for a nucleic acid “derived from” (another) nucleic acid, means that the nucleic acid, which is derived from (another) nucleic acid, shares at least 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity or are identical with the nucleic acid from which it is derived. In the context of amino acid sequencesthe term “derived from” means that the amino acid sequence, which is derived from (another) amino acid sequence, shares at feast 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity or are identical with the amino acid sequence from which it is derived. Fragment: If not defined differently in a specific context, the term “fragment’ as used herein typically refers to a shorter portion of a reference sequence of e.g. a nucleic acid or an amino acid sequence. A fragment typically consists of a sequence that is identical to the corresponding stretch within the reference sequence. A fragment may consist of a continuous stretch of entities, such as nucleotides or amino acids, corresponding to a continuous stretch of entities in the molecule the fragment is derived from, representing at least 50%, 60%, 70%, 80%, 85%, 90%, 95% of the sequence.
[0024] Identity (of a sequence): The term “identity” as used herein in the context of nucleic acid sequences, or amino acid sequences, refers to the percentage to which two sequences are identical. To determine the percentage to which two sequences are identical, the sequences can be aligned (by also introducing gaps, if necessary) to be subsequently compared to one another. In the context of the invention, the substitution of a nucleotide by a modified nucleotide (e.g. U substituted by with Nl-methylpseudouridine) shall not be considered for calculating percent identity. The percentage to which two sequences are identical can e.g. be determined using an algorithm, e.g. an algorithm integrated in BLAST.
[0025] Variant (of a sequence): The term “variant” as used herein in the context of a nucleic acid sequence refers to a nucleic acid sequence derived from a reference nucleic acid sequence. Such a variant may exhibit one or more nucleotide deletions, insertions, additions and / or substitutions compared to the reference nucleic acid from which the variant is derived from. A variant may be a functional variant in the sense that the variant has retained at least 70%, 80%, 90%, or 95% or more of the function of the sequence where it is derived from. A “variant” of a nucleic acid sequence may have at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity over a stretch of at least 30, 50, 75 or 100 nucleotides. The term “variant” as used herein in the context of proteins or peptides refers to a protein or peptide having an amino acid sequence which differs from the reference sequence in one or more mutation(s) substitution(s), such as one or more substituted, inserted and / or deleted amino acid(s). A variant of a peptide or protein may be a functional variant, which means that the variant exerts essentially the same, or at least 70%, 80%, 90% or 95% or more of the function of the peptide or protein it is derived from. A “variant” of a peptide or protein may have at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity over a stretch of at least 30, 50, 75 or 100 amino acids.
[0026] Detailed Description of the invention
[0027] The present application is filed together with a sequence listing in electronic format, which is part of the description (WIPO standard ST.26; SEQ ID NO: 1-667). The information contained in the sequence listing is incorporated herein by reference in its entirety. Where reference is made to “SEQ ID NOs” of other published patent applications or patents, said sequences, e.g. amino acid sequences or nucleic acid sequences, are explicitly incorporated herein by reference.
[0028] 1: Artificial RNA:
[0029] In a first aspect, the invention provides an artificial RNA.
[0030] It must be noted that specific features and embodiments that are described in the context of the first aspect, that is the artificial RNA of the invention, are likewise applicable to any other aspect of the invention.The term “artificial RNA” as used herein refers to an RNA that does not occur naturally and may hence be understood as a non-natural RNA molecule. RNA molecules may be non-natural due to their individual sequence (e.g. G / C content) and / or due to other modifications, e.g. structural modifications. An artificial RNA may comprise at least one heterologous sequence element, e.g. a heterologous UTR. Typically, an artificial RNA may be generated by genetic engineering to correspond to a desired sequence of nucleotides. The term is not restricted to “one single molecule” but may comprise an ensemble of essentially identical nucleic acid molecules.
[0031] In embodiments, the artificial RNA is an isolated RNA. The term “isolated RNA” does not encompass a cell or a subject that comprises said RNA but relates to the RNA as an isolated molecule or ensemble of isolated molecules. The “isolated RNA” can e.g. be isolated or purified from a cell or can be an RNA isolated from an RNA in vitro transcription.
[0032] Minimized Gnas 3’ UTR sequence element:
[0033] The artificial RNA comprises at least one minimized Gnas 3’ UTR sequence element (herein referred to as “Gnas-min”). In embodiments, the artificial RNA comprises at least one 3' untranslated region (3' UTR) comprising at least one minimized Gnas 3’ UTR sequence element (Gnas-min) as defined herein.
[0034] The term “untranslated region” and the respective abbreviation “UTR” refers to a part of the RNA that is n translated into a peptide or protein and that is typically located 5’ or 3’ of a coding sequence. A UTR may comprise elements for controlling gene expression (regulatory elements). Such regulatory elements may be, e.g., ribosomal binding sites, promotor elements. Regulatory elements may determine turnover, stability, and localization of the nucleic acid, particularly the RNA. UTRs may also harbour sequence elements that enhance translation.
[0035] A 3-UTR is typically located between a coding sequence and an (optional) poly(A) sequence. A 3-UTR may comprise elements for controlling expression, also called regulatory elements. Such regulatory elements may be, e.g., ribosomal binding sites, miRNA binding sites, etc.
[0036] A Gnas 3’ UTR sequence is selected or derived from a 3’UTR of a gene encoding a Guanine nucleotide-binding protein G(s) subunit alpha isoforms short (Gnas), or a homolog, variant or fragment thereof. A Gnas 3' UTR preferably comprises or consists of a nucleic acid sequence which is derived from the 3' UTR of a Guanine nucleotide-binding protein G(s) subunit alpha isoforms short (“Gnas” or “Gnas.1”) gene, preferably from a vertebrate Guanine nucleotide-binding protein G(s) subunit alpha isoforms short (Gnas) gene, more preferably from a mammalian (e.g. human) Guanine nucleotide-binding protein G(s) subunit alpha isoforms short (Gnas) gene, most preferably from a mus musculus Guanine nucleotide-binding protein G(s) subunit alpha isoforms short (Gnas) gene, or a homolog, variant or fragment thereof.
[0037] The term “minimized”, in particular when used in the context of a Gnas 3’ UTR sequence, has to be understood in its broadest sense, namely referring to any possible nucleic acid sequence that is shorter than the corresponding full length Gnas 3’ UTR sequence. Consequently, the term “minimized Gnas 3’ UTR sequence element’ does not encompass a full length Gnas 3’ UTR sequence.
[0038] The artificial RNA of the invention does not comprise a full length Gnas 3' UTR sequence.A “minimized Gnas 3’ UTR sequence element’ (Gnas-min) may comprise or consist 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, 40%, 39%, 38%, 37%, 36%, 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15% of a nucleic acid sequence section taken from a corresponding full length Gnas 3’ UTR sequence, or a variant thereof. A “minimized Gnas 3’ UTR sequence element” (Gnas-min) may comprise or consist of 350, 349, 348, 347, 346, 345, 344, 343, 342, 341, 340, 339, 338, 337, 336, 335, 334, 333, 332, 331, 330, 329, 328, 327, 326, 325, 324, 323, 322, 321, 320, 319, 318, 317, 316, 315, 314, 313, 312, 311, 310, 309, 308, 307, 306, 305, 304, 303, 302, 301, 300, 299, 298, 297, 296, 295, 294, 293, 292, 291 , 290, 289, 288, 287, 286, 285, 284, 283, 282, 281 , 280, 279, 278, 277, 276, 275, 274, 273, 272, 271, 270, 269, 268, 267, 266, 265, 264, 263, 262, 261, 260, 259, 258, 257, 256, 255, 254, 253, 252, 251, 250, 249, 248, 247, 246, 245, 244, 243, 242, 241 , 240, 239, 238, 237, 236, 235, 234, 233, 232, 231 , 230, 229, 228, 227, 226, 225, 224, 223, 222, 221, 220, 219, 218, 217, 216, 215, 214, 213, 212, 211, 210, 209, 208, 207, 206, 205, 204, 203, 202, 201, 200, 199, 198, 197, 196, 195, 194, 193, 192, 191, 190, 189, 188, 187, 186, 185, 184, 183, 182, 181, 180, 179, 178, 177, 176, 175, 174, 173, 172, 171, 170, 169, 168, 167, 166, 165, 164, 163, 162, 161, 160, 159, 158, 157, 156, 155, 154, 153, 152, 151, 150, 149, 148, 147, 146, 145, 144, 143, 142, 141, 140, 139, 138, 137, 136, 135, 134, 133, 132, 131, 130, 129, 128, 127, 126, 125, 124, 123, 122, 121, 120, 119, 118, 117, 116, 115, 114, 113, 112, 111, 110, 109, 108, 107, 106, 105, 104, 103, 102, 101, 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71 , 70, 69, 68, 67, 66, 65, 64, 63, 62, 61 , 60, 59, 58, 57, 56, 55, 54, 53, 52, 51 , 50, 49, 48, 47, 46, 45, 44, 43, 42, 41 , 40, 39, 38, 37, 36, 35, 34, 33, 32, 31 , 30 consecutive nucleotides taken from a corresponding full length Gnas 3’ UTR sequence, or a variant thereof.
[0039] In embodiments, Gnas-min comprises less than, with increasing preference, 350, 300, 250, 200, 190, 180, 170, 160 consecutive nucleotides taken from a corresponding frill length Gnas 3’ UTR sequence, or a variant of said full length Gnas 3’ UTR sequence.
[0040] In embodiments, Gnas-min comprises or consists of a section of, with increasing preference, 30 to 350, 50 to 250, 70 to 200, 80 to 150, 90 to 140, 100 to 130, 110 to 120 consecutive nucleotides, wherein the section is taken from the full length Gnas 3’ UTR sequence.
[0041] In embodiments, the full length Gnas 3’ UTR sequence comprises or consists of a nucleic acid sequence that is identical to or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 8.
[0042] In embodiments, the artificial RNA comprises
[0043] at least one coding sequence (cds);
[0044] at least one 3’ untranslated region (3’ UTR) comprising at least one minimized Gnas 3’ UTR sequence element (Gnas-min) as defined herein.
[0045] The term “coding sequence” and the corresponding abbreviation “cds” refers to a sequence of several nucleotide triplets that can be translated into a peptide or protein. A “cds” is an RNA sequence consisting of several nucleotides that may be divided by three, which typically starts with a start codon and preferably terminates with a stop codon.In the context of the invention, it is particularly advantageous that Gnas-min consists of a section that is taken from the 3’ terminal sequence region of a Gnas 3’ UTR sequence. Without wishing to be bound to theory, the 3’ terminal sequence region of a Gnas 3’ UTR sequence comprises A and A / U rich sequence elements that may be responsible for binding of binding proteins that improve translation and in vivo stability of the artificial RNA of the invention. Moreover, the 3’ terminal region of a Gnas 3’ UTR sequence may recruit Poly(A)-binding proteins.
[0046] A particularly preferred 3’ terminal sequence region of a Gnas 3’ UTR from which Gnas-min may be derived from contains the 3’ terminal 150 nucleotides of the Gnas 3’ UTR (herein referred to as “Gnas150”). Preferably, Gnas150 has a nucleic acid sequence that is identical to or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (e.g. SEQ ID NO: 6 or 7). Across the Gnasl 50 nucleotide sequence, several Poly(A)-binding or RNA binding proteins such as, inter alia, PABPC1, RBMY1A1, SFRS13A, KHDRBS3 (according to RBP nomenclature) may potentially bind and have a positive impact on expression of an encoded protein when administered to a cell or subject.
[0047] Suitably, a “minimized Gnas 3’ UTR sequence element” according to the invention comprises, with increasing preference, at least 50% A nucleotides, at least 51 % A nucleotides, at least 52% A nucleotides, at least 53% A nucleotides, at least 54% A nucleotides, at least 55% A nucleotides.
[0048] A “minimized Gnas 3’ UTR sequence element’ may comprise or consist 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, 49%, 48%, 47%, 46%, 45%, 44%, 43%, 42%, 41%, 40%, 39%, 38%, 37%, 36%, 35%, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15% of a nucleic acid sequence section taken from a Gnasl 50 sequence, or a variant thereof.
[0049] A “minimized Gnas 3’ UTR sequence element” may likewise comprise or consist of 150, 149, 148, 147, 146, 145, 144, 143, 142, 141, 140, 139, 138, 137, 136, 135, 134, 133, 132, 131, 130, 129, 128, 127, 126, 125, 124, 123, 122, 121, 120, 119, 118, 117, 116, 115, 114, 113, 112, 111, 110, 109, 108, 107, 106, 105, 104, 103, 102, 101, 100, 99, 98,97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, 65, 64, 63, 62, 61, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, 50, 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30 consecutive nucleotides taken from a Gnasl 50 sequence, or a variant thereof.
[0050] The “minimized Gnas 3’ UTR sequence element” may comprises or consists of a section of, with increasing preference, 30 to 150, 40 to 150, 50 to 150, 60 to 150, 70 to 150 consecutive nucleotides, wherein the section is taken from a Gnasl 50 nucleic acid sequence that is identical to or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0051] In various suitable embodiments, Gnas-min consists of a section of 70 to 150 consecutive nucleotides, wherein the section is taken from a Gnasl 50 nucleic acid sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).In embodiments, Gnas-min consists of a section of, with increasing preference, 80 to 150, 90 to 140, 100 to 130, 110 to 120, consecutive nucleotides, wherein the section is taken from a Gnasl 50 nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0052] In preferred embodiments, Gnas-min consists of a section of 110 to 120 consecutive nucleotides, wherein the section is taken from a Gnasl 50 nucleic acid sequence identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%>, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0053] In various suitable embodiments, Gnas-min consists of a section of 70, 71 , 72, 63, 74, 75, 86, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 consecutive nucleotides, wherein the section is taken from a Gnasl 50 nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0054] In preferred embodiments in this context, Gnas-min consists of a section of, with increasing preference, 110, 111, 112, 113. 114 consecutive nucleotides, wherein the section is taken from a Gnasl 50 nucleic acid sequence identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7), or Gnas-min consists of a section of, with increasing preference, 120. 119. 118. 117. 116. 115. 114 consecutive nucleotides, wherein the section is taken from a Gnasl 50 nucleic acid sequence identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0055] In embodiments, Gnas-min consists of a section of consecutive nucleotides as defined herein, wherein the section is preferably taken from the 3’ terminal end of the Gnasl 50 nucleic acid sequence. Accordingly, in such embodiments, the 3'-tenninal most nucleotides of Gnasl 50 are present in Gnas-min, and are therefore not 3’ terminally truncated (e.g. a section of 110 consecutive nucleotides taken from the 3’ terminal end of Gnasl 50 would comprise all 1103'-terminal most nucleotides of Gnasl 50, and, e.g., a section of 120 nucleotides taken from the 3’ terminal end of Gnasl 50 would comprise all 1203'-terminal most nucleotides of Gnasl 50, etc.).
[0056] Accordingly, in embodiments, Gnas-min consists of a section as defined herein, wherein the respective section is preferably taken from the 3’ terminal end of a Gnasl 50 nucleic acid sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0057] Accordingly, in embodiments in this context,
[0058] Gnas-min consists of a section of 70 to 150 consecutive nucleotides, wherein the section is taken from the 3’ terminal end of a Gnasl 50 nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7);Gnas-min consists of a section of, with increasing preference, 80 to 150, 90 to 140, 100 to 130, 110 to 120 consecutive nucleotides, wherein the section is taken from the 3’ terminal end of a Gnasl 50 nucleic acid sequence identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7);
[0059] Gnas-min preferably consists of a section of 110 to 120 consecutive nucleotides, wherein the section is taken from the 3’ terminal end of a Gnasl 50 nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7);
[0060] - Gnas-min consists of a section of 70, 71 , 72, 63, 74, 75, 86, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 consecutive nucleotides, wherein the section is taken from the 3’ terminal end of a Gnasl 50 nucleic acid sequence identical to, or at feast 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7);
[0061] Gnas-min consists of a section of, with increasing preference, 110, 111, 112, 113, 114 consecutive nucleotides, wherein the section is taken from the 3’ terminal end of a Gnas150 nucleic acid sequence identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7), or Gnas-min consists of a section of, with increasing preference, 120, 119, 118, 117, 116, 115, 114 consecutive nucleotides, wherein the section is taken from the 3’ terminal end of a Gnasl 50 nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0062] In the following, preferred Gnas-min nucleic acid sequences are described, with reference to specific SEQ ID NOs that are provided in the ST.26 sequence listing. It should be noted that only exemplary Gnas-min sequences are provided as modified nucleotide sequences in the ST.26 sequence listing. All other Gnas-min nucleic acid sequences that are provided in non-modified form in the St.26 sequence listing (e.g. comprising Uracil nucleotides) may optionally comprise sequence modifications such as modified Uracil nucleotides as further specified in section “modified nucleotides”. In embodiments, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1 -3, 5-7, 53-607, or a modified version of any of these, preferably an N1 -methylpseudouridine (ml qj)-modified sequence version of any of these.
[0063] In embodiments, Gnas-min comprises a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 132-212, preferably SEQ ID NOs: 168-212.
[0064] In embodiments where Gnas-min is taken from the 3’ terminal end of a Gnasl 50 nucleic acid sequence, Gnas-min is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1 -3, 5-7, 53-131.In embodiments where Gnas-min is taken from a section of 110 to 120 consecutive nucleotides of a Gnas150 nucleic acid sequence, Gnas-min is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1 -3, 82-91 , 213-607.
[0065] In preferred embodiments where Gnas-min is taken from a section of 110 to 120 consecutive nucleotides from the 3’ terminal end of a Gnasl 50 nucleic acid sequence, Gnas-min is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 82-91.
[0066] In more preferred embodiments, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3
[0067] In even more preferred embodiments, Gnas-min consists of a ip or ml ip modified nucleotide sequence identical to SEQ ID NO: 2 or 3. In particularly preferred embodiments, Gnas-min consists of a ml ip modified nucleotide sequence identical to SEQ ID NO: 2.
[0068] In embodiments, the 3’ UTR region of the artificial RNA of the invention comprises only one Gnas-min as defined herein. In embodiments, the artificial RNA does not comprise a section of more than 150 consecutive nucleotides, e.g. 200, 250, 300 nucleotides, from a full length Gnas 3’ UTR sequence according to SEQ ID NO: 8. In preferred embodiments, the artificial RNA does not comprise a nucleic acid sequence according to SEQ ID NO: 4.
[0069] The artificial RNA of the invention does not comprise a nucleic acid sequence according to SEQ ID NO: 8.
[0070] 5’ UTR sequence element:
[0071] In embodiments, the artificial RNA comprises at least one 5’ untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element.
[0072] A 5’-UTR is typically located in 5’ direction of the cds. A 5-UTR typically starts with the transcriptional start site and ends before the start codon of the cds. A 5'-UTR may comprise elements for controlling gene expression, called regulatory elements. Such regulatory elements may be, e.g., ribosomal binding sites, miRNA binding sites.
[0073] Suitably, the at least one 5-UTR sequence element is derived from a gene that encodes an RNA with prolonged halflife. In some embodiments, the at least one 5-UTR comprises one or more of a binding site for proteins that affect nucleic acid stability or location in a cell, or one or more miRNA or binding sites for miRNAs.
[0074] In embodiments, the 3’ UTR sequence element and / or the 5’ UTR sequence element is heterologous to the cds. The term “heterologous” or “heterologous UTR” refers to a nucleic acid or UTR that is not from the same gene, the same genomic fusion, or the same naturally occurring transcript. Heterologous sequences or heterologous UTRs do naturally (that is, in nature) not occur in the same nucleic acid molecule.
[0075] In embodiments, the at least one 5' UTR sequence element comprises a nucleic acid sequence derived or selected from a 5-UTR of HSD17B4, AIG1 , alpha-globin (HBA1 , HBA2), ASAH1 , ATP5A1 , COX6C, DPYSL2, HHV5, MDR,MP68, NDUFA4, NOSIP, RPL31, RPL32, RPL35A, SLC7A3, synthetic origin, TUBB4B, UBQLN2, or from a homolog, a fragment or variant of any one of these.
[0076] Accordingly, the artificial RNA may comprise the following combinations of 5’ UTR sequence element and 3’ UTR sequence element (5’UTR / 3’UTR): gn1 (HSD17B4 / Gnas-min); gn2 (AIG1 / Gnas-min); gn3 (alpha-globin (HBA1, HBA2) / Gnas-min); gn4 (ASAH1 / Gnas-min); gn5 (ATP5A1 / Gnas-min); gn6 (COX6C / Gnas-min); gn7 (DPYSL2 / Gnas-min); gn8 (HHV5 / Gnas-min); gn9 (MDR / Gnas-min); gn10 (MP68 / Gnas-min); gn11 (NDUFA4 / Gnas-min); gn12 (NOSIP / Gnas-min); gn13 (RPL31 / Gnas-min); gn14 (RPL32 / Gnas-min); gn15 (RPL35A / Gnas-min); gn16 (SLC7A3 / Gnas-min); gn17 (TUBB4B / Gnas-min); or gn18 (UBQLN2 / / Gnas-min).
[0077] Preferably, the artificial RNA comprises a combination of 5’ UTR sequence element and 3’ UTR sequence element (5’UTR / 3'UTR) according to “gn1” (HSD17B4 / Gnas-min).
[0078] In the following, preferred 5-UTR nucleic acid sequences are provided, with reference to specific SEQ ID NOs provided in the ST.26 Sequence listing. Even though only some exemplary 5-UTR nucleic acid sequences are provided as modified nucleotide sequences, all the other 5-UTR nucleic acid sequences may optionally comprise sequence modifications such as modified Uracil nucleotides as further specified in section “modified nucleotides”.
[0079] In embodiments, the at least one 5’-UTR sequence element that is derived or selected from HSD17B4, AIG1 , alpha-gbbin (HBA1, HBA2), ASAH1 , ATP5A1 , COX6C, DPYSL2, HHV5, MDR, MP68, NDUFA4, NOSIP, RPL31, RPL32, RPL35A, SLC7A3, synthetic origin, TUBB4B, or UBQLN2 comprises or consist of a nucleic acid sequence being identical to, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 24-52, or a fragment ora variant of any of these, preferably an N1 -methylpseudouridine (mlip)-modified sequence version thereof.
[0080] In preferred embodiments, the at least one 5-UTR sequence element is derived or selected from a HSD17B4 gene, wherein the at least one 5’-UTR sequence element comprises or consists of a nucleic acid sequence being identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 24-26, or a fragment or a variant thereof.
[0081] In particularly preferred embodiments, the at least one 5-UTR sequence element consists of a nucleic acid sequence being identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 25, or a fragment or a variant thereof.
[0082] In preferred embodiments of the invention, the at least one 5-UTR region comprises a HSD17B45’ UTR sequence element as defined herein, preferably SEQ ID NOs: 24-26, and the at least one 3-UTR region that comprises a Gnas- min as defined herein, preferably SEQ ID NOs: 1-3. Accordingly, the artificial RNA comprises at least one coding sequence as defined herein linked to a HSD17B45’-UTR sequence element as defined herein and a Gnas-min 3-UTR sequence element as defined herein (5’UTR / 3’UTR combination: gn1).
[0083] The 5’UTR / 3’UTR combination gn1 is particularly advantageous in the context of the invention as both sequence elements are short (e.g., a preferred version of the HSD17B45’ UTR sequence has a length of 62 nucleotides, and apreferred version of Gnas-min has a length of 70 to 150 nucleotides), but, nonetheless, this UTR combination results in exceptionally improved expression when e.g. administered to a cell or a subject.
[0084] Furthermore advantageously, an artificial RNA that comprises the 5’UTR / 3’UTR combination gn1 can be produced at high quality, even in embodiments where the artificial RNA comprises large coding sequences (e.g. a cds that has a length of at least 3500 nucleotides, 4000 nucleotides, 4500 nucleotides) which leads so very long RNA sequences. Therefore, using the 5’UTR / 3’UTR combination gn1 as defined herein has advantages when it comes to manufacturability of the artificial RNA, in particular in embodiments where the artificial RNA comprises 3500 to 10000 nucleotides, preferably 3500 to 7500 nucleotides, more preferably 3500 to 5000 nucleotides.
[0085] Moreover, the 5’UTR / 3’UTR combination gn1 as defined herein allows for the use of modified nucleotides (e.g. modified uridine nucleotide such as, e.g. pseudouridine (ip) or N1 -methylpseudouridine (ml ip)) without a translational loss / a reduction in translation efficiency.
[0086] Embodiments that relate to the use of modified nucleotides are specifically described in the following section.
[0087] Modified nucleotides:
[0088] Advantageously, the artificial RNA comprising Gnas-min can be modified with modified nucleotides without a translational loss / a reduction in translation efficiency. Translation efficiency is very often negatively affected by chemical modification of the 3’ UTR of an RNA because it is believed that protein interaction is reduced by such chemical modifications. As the 3' UTR region has a paramount importance for regulating the in vivo translation of an RNA into a protein, hampering protein interactions with e.g. factors that impact RNA stability and / or translation is not desired. As Gnas-min comprises A / U rich sequences, it was a surprising and unexpected finding that Gnas-min can be modified (e.g. by using modified uridine nucleotide such as, e.g. pseudouridine (ip) or N1-methylpseudouridine (m1ip)) essentially without a translational loss / a reduction in translation efficiency.
[0089] Moreover, the 5’UTR / 3’UTR combination gn1 is particularly suitable for the use of modified nucleotides (e.g. modified uridine nucleotide such as, e.g. pseudouridine (ip) or N1 -methylpseudouridine (ml ip)) essentially without a translational loss / a reduction in translation efficiency.
[0090] In embodiments, the artificial RNA, in particular Gnas-min, comprises at least one modified nucleotide, wherein the modification preferably refers to chemical modifications comprising backbone modifications, sugar modifications or base modifications.
[0091] A backbone modification is a chemical modification in which phosphates of the backbone of the nucleotides of the RNA are modified. A sugar modification is a chemical modification of the sugar of the nucleotides of the RNA. A base modification is a chemical modification of the base moiety of the nucleotides of the RNA. In this context, nucleotide analogs are preferably selected from nucleotide analogs which are applicable for transcription and / or translation. In embodiments, the artificial RNA, in particular Gnas-min, comprises at least one modified nucleotide selected from WO2021239880 [p.136, line 17 to p.137, line 19], which is hereby incorporated by reference. In embodiments, the RNA may comprise modified uridine nucleotides that preferably comprise a chemical modification in the 5-position of theuracil. Suitable modified uridine nucleotides may be selected from WO2021239880 [p.137, lines 15 to 19], which is hereby incorporated by reference. Suitably, the Gnas-min nucleic acid sequence at least one modified uridine nucleotide that preferably comprises a chemical modification in the 5-position of the uracil.
[0092] In embodiments, the artificial RNA, in particular Gnas-min, comprises at least one modified uridine nucleotide.
[0093] In some embodiments, the at least one modified nucleotide is selected from pseudouridine, N1 -methylpseudouridine, N1 -ethylpseudouridine, 2-thiouridine, 4’-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1 -deaza¬ pseudouridine, 2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2’-O-methyl uridine.
[0094] In preferred embodiments, the artificial RNA, in particular Gnas-min, comprises at least one modified uridine nucleotide that comprises a chemical modification in the 5-position of the uracil. In some embodiments, essentially all, e.g. essentially 100% of the uracil of the RNA sequence, in particular the Gnas-min sequence, have a chemical modification, preferably a chemical modification in the 5-position of the uracil (e.g. ip and / or ml ip).
[0095] In preferred embodiments, the artificial RNA, in particular Gnas-min, comprises at least one modified nucleotide selected from pseudouridine (ip) or N1 -methylpseudouridine (ml ip). In particularly preferred embodiments, the at least one modified nucleotide is selected from N1 -methylpseudouridine (ml ip).
[0096] In embodiments, 100% of the uracil in the nucleic acid sequence of the artificial RNA, in particular of Gnas-min, comprise a chemical modification, preferably a chemical modification in the 5-position of the uracil.
[0097] In preferred embodiments, 100% of the uracil in the nucleic acid sequence of the artificial RNA (including Gna-min) are substituted with pseudouridine (ip) or N1 -methylpseudouridine (m1ip). In particularly preferred embodiments, 100% of the uracil in the nucleic acid sequence of Gnas-min are substituted with N1 -methylpseudouridine (ml ip).
[0098] To be noted, any nucleic acid sequence as defined herein (e.g., Gnas-min, 5’ UTR sequences such as HSD17B4, coding sequence, histone stem loop (hsl), Kozak sequence, 3'-terminal sequence, 5'-terminal sequence, Poly(N)sequence, etc.) that may be comprised in the artificial RNA of the invention suitably comprise a modified nucleotide as defined herein, preferably a modified uridine nucleotide as defined herein, most preferably 100% of the uracil in said nucleic acid sequence comprise a chemical modification, preferably pseudouridine (ip) or N1- methylpseudouridine (m1ip). Thus, any of the nucleic acid sequences according to SEQ ID NOs: 1, 5, 9, 12, 15-24, 27-52, 53-607, 608, 611, 614, 619-630 can optionally comprise at least one modified nucleotide as defined herein, preferably a modified uridine nucleotide as defined herein, most preferably 100% of the uracil in said nucleic acid sequence canprise a chemical modification, preferably pseudouridine (ip) or N1-methylpseudouridine (ml ip).
[0099] Accordingly, in preferred embodiments, Gnas-min consists of a section of 70 to 150 consecutive nucleotides, wherein the section is taken from a pseudouridine (ip) or N1 -methylpseudouridine (m1ip) modified nucleic add sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 6 or 7.In embodiments in this context, Gnas-min consists of a section of, with increasing preference, 80 to 150, 90 to 140, 100 to 130, 110 to 120, consecutive nucleotides, wherein the section is taken from a pseudouridine (rp) or N1-methylpseudouridine (ml ip) modified nucleic acid sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 6 or 7.
[0100] In preferred embodiments in this context, Gnas-min consists of a section of 110 to 120 consecutive nucleotides, wherein the section is taken from a pseudouridine (ip) or N1-methylpseudouridine (ml ip) modified nucleic add sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 6 or 7.
[0101] In embodiments in this context, wherein Gnas-min consists of a section of 70, 71 , 72, 63, 74, 75, 86, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 consecutive nucleotides, wherein the section is taken from a pseudouridine (ip) or N1-methylpseudouridine (ml ip) modified nucleic add sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 6 or 7.
[0102] Suitably, the respective sections as defined above are taken from the 3’ terminal end of the pseudouridine (ip) or N1 -methylpseudouridine (ml ip) modified nucleic acid sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 6 or 7.
[0103] In preferred embodiments in this context, the respective sections as defined above are taken from a N1-methylpseudouridine (ml ip) nucleic acid sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 6.
[0104] Accordingly, in embodiments, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1-3, 5-7, 53-607, wherein the 100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with pseudouridine (ip) or N1-methylpseudouridine (m1ip). In particularly preferred embodiments in this context, 100% of the uracil in the nucleic acid sequence are substituted with N1 -methylpseudouridine (m1ip).
[0105] In preferred embodiments, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1-3, 82-91 , wherein the 100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with pseudouridine (ip) or N1-methylpseudouridine (m1ip). In particularly preferred embodiments in this context, 100% of the uracil in the nucleic acid sequence are substituted with N1-methylpseudouridine (ml ip).
[0106] In particularly preferred embodiments in this context, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 3 (100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with pseudouridine (ip)) or SEQ ID NO: 2 (100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with N1 -methylpseudouridine (ml ip)).In embodiments the artificial RNA comprises at least one pseudouridine (qj) HSD17B45’-UTR sequence or at least one N1 -methylpseudouridine modified HSD17B45’-UTR sequence. In preferred embodiments in this context, 100% of the uracil in the nucleic acid sequence of HSD17B45’-UTR sequence are substituted with N1 -methylpseudouridine.
[0107] Accordingly, the at least one HSD17B45’-UTR sequence element may comprise or consist of a nucleic acid sequence being identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 24- 26, or a fragment or a variant thereof, wherein the 100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with pseudouridine (qj) or N1 -methylpseudouridine (m1qi). In particularly preferred embodiments in this context, 100% of the uracil in the nucleic acid sequence are substituted with N1-methylpseudouridine (m1qr).
[0108] In particularly preferred embodiments in this context, the HSD17B45-UTR sequence comprises or consists of a nucleotide sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to identical to SEQ ID NO: 26 (100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with pseudouridine (qi)) or SEQ ID NO: 25 (100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with N1-methylpseudouridine (ml qj)).
[0109] In most preferred embodiments, the artificial RNA of the invention comprises a N1-methylpseudouridine (m1qr) modified HSD17B45'-UTR sequence element according to SEQ ID NO: 25, and a N1 -methylpseudouridine modified Gnas-min 3’ UTR element according to SEQ ID NO: 2.
[0110] RNA molecules of the invention that comprise modified nucleotides as defined herein (e.g., N1-methylpseudouridine (ml qj)) are beneficial to provide a therapeutic peptide or protein as defied herein (e.g., a CRISPR-associated endonuclease) as unwanted immune responses caused by the artificial RNA can be strongly reduced.
[0111] Poly(N)seciuences:
[0112] In embodiments, the artificial RNA comprises at least one poly(N) sequence, e.g. at least one poly(A) sequence, at least one poly(U) sequence, at least one poly(C) sequence, or combinations thereof.
[0113] In embodiments, the artificial RNA comprises at least one poly(A) sequence.
[0114] In some embodiments, the artificial RNA comprises at least two, three, or more poly(A) sequences.
[0115] The term “poly(A) sequence” refers to a sequence of up to 1000 adenosines typically located at the 3’-end or in proximity of the 3’-end of a linear RNA Typically, a poly(A) sequence is homopolymeric. Alternatively, a poly(A) sequence may be interrupted by at hast one nucleotide different from an adenosine.
[0116] In embodiments, the at least one poly(A) sequence comprises, with increasing preference, 20 to 500 adenosine nucleotides, 40 to 250 adenosine nucleotides, 60 to 200 adenosine nucleotides, 60 to 150 adenosine nucleotides. In preferred embodiments, the at least one poiy(A) sequence comprises 60 to 150 adenosine nucleotides.
[0117] In embodiments, the at least one poly(A) sequence comprises about 64, about 80, about 100, about 120 adenosine nucleotides, about 140 adenosine nucleotides. In preferred embodiments, the at least one poly(A) sequence comprises about 100 adenosine nucleotides.In embodiments, the at least one poly(A) sequence is interrupted by non-adenosine nucleotides, preferably by about 10 non-adenosine (N10) nucleotides. In embodiments in this context, the artificial RNA comprises at feast one interrupted poly(A) sequence, wherein the poly(A) sequence is interrupted by non-adenosine nucleotides, preferably by about 10 non-adenosine (N10) nucleotides. In embodiments in this context, the at least one poly(A) sequence comprises a A30-N10-A70 sequence.
[0118] The at least one poly(A) sequence as defined herein may be located directly at the 3’ terminus of the RNA In such embodiments, the 3’-terminal nucleotide in the polynucleotide chain is the 3’-terminal A nucleotide of the at least one poly(A) sequence as defined herein. In other words, the 3’ terminus of the artificial RNA consists of a poly(A) sequence (e.g. A100 or A30-N10-A70) and therefore terminates with an A. Accordingly, in embodiments, the at least one poly(A) sequence is located directly at the 3’ terminus of the artificial RNA thereby representing the 3’ terminal sequence end of the artificial RNA
[0119] Advantageously, having a 3’ terminus ending on an adenosine may decrease the induction of interferons, e.g. IFNalpha, induced by the artificial RNA of the invention if, e.g., administered as a medicament to a human. This is important as the induction of interferons, e.g. IFNalpha, is thought to be one main factor for induction of side effects.
[0120] In particularly preferred embodiments, the artificial RNA comprises a poly(A) sequence of 100 consecutive adenosines (A100) located directly at the 3’ terminus of the RNA.
[0121] In alternative embodiments, the artificial RNA comprises at least one poly(A) sequence obtained by enzymatic polyadenylation, wherein the majority of RNA molecules comprise about 100 (+ / - 20) to about 500 (+ / - 100) adenosine nucleotides, preferably about 100 (+ / - 20) to about 200 (+ / - 40) adenosine nucleotides.
[0122] Histone stem-loop sequences:
[0123] In embodiments, the artificial RNA comprises at least one histone stem-loop (hsl). A hsl may be located in the 3’ region of the artificial RNA The term refers to a nucleic acid sequence that forms a stem-loop secondary structure. A hsl may be derived from formulae (I) or (II) of WO2012019780, or preferably from the specific formulae (la) or (Ila) of WO2012019780, that are hereby incorporated by reference.
[0124] In preferred embodiments, the at least one hsl sequence comprises or consists of a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 16, or a fragment or variant thereof, preferably an N1 -methylpseudouridine (ml ip)-modified sequence version thereof.
[0125] In preferred embodiments, the at least one hsl sequence is located between the Gnas-min sequence element as defined herein and the poly(A) sequence as defined herein.
[0126] In embodiments, the artificial RNA comprises a 3’-terminal sequence element. The 3’-terminal sequence element represents the 3’ terminus of the RNA. A 3’-terminal sequence element may comprise at least one poly(A) sequence as defined herein and, optionally, at least one hsl as defined herein. The 3’-terminal sequence element is located in 3’ direction from Gnas-min.In embodiments, the at least one 3’-terminal sequence element comprises or consists of a nucleic acid sequence being identical or at feast 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: IT-23, or a fragment or variant of these sequences, preferably an N1 -methylpseudouridine (ml qj)-modified sequence version of any of these. In preferred embodiments, the at least one 3’-terminal sequence element (comprising a hsl followed by A100) comprises or consists of a nucleic acid sequence being identical or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 17, or a fragment or variant thereof, preferably an N1 -methylpseudouridine (m1qj (-modified sequence version of any of these.
[0127] Preferably, the 3’ terminus of the artificial RNA has the following structure:
[0128] Gnas-min - hsl - Poly(A)
[0129] Gnas-min - Poly(A)
[0130] Gnas-min - hsl - Poly(A100)
[0131] Gnas-min - Poly(A100)
[0132] Cap structures:
[0133] In embodiments, the artificial RNA comprises a 5’-cap structure.
[0134] The term “5’-cap structure” refers to a 5’ modified nucleotide, particularly a guanine nucleotide, positioned at the 5’-end of an RNA The 5’-cap structure is typically connected via a 5’-5’-triphosphate linkage to the RNA. A 5’-cap structure may stabilize the RNA and / or may enhance expression of the encoded peptide or protein and / or may reduce the stimulation of the innate immune system after administration.
[0135] In embodiments, the artificial RNA comprises a 5’-cap structure selected from m7G, capO, cap1 , cap2, or a modified version of any of these.
[0136] In preferred embodiments, the artificial RNA comprises a 5’-cap1 structure.
[0137] Suitably, the 5’-cap structure is formed during RNA in vitro transcription using a cap analog.
[0138] The term “cap analog” refers to a non-polymerizable di-nucleotide or trinucleotide that has cap functionality in that it facilitates translation or localization, and / or prevents degradation of an RNA when incorporated at the 5’-end of the molecule. Non-polymerizable means that the cap analog will be incorporated only at the 5’-terminus because it does not have a 5’ triphosphate and therefore cannot be extended in the 3’-direction e.g. by an RNA polymerase.
[0139] In embodiments, a cap1 or a modified cap1 structure is generated using a cap analog, preferably a tri-nucleotide cap analog. Any cap analog derivable from the structures defined in claims 1 -13 of WO2017053297 (hereby incorporated by reference) or, alternatively, any cap analog derivable from the structures defined in claims 1-37 of W02023007019 (hereby incorporated by reference) may be suitably used to co-transcnptionally generate a cap1 or a modified cap 1. In embodiments, the artificial RNA comprises a cap1 structure m7G(5’)ppp(5’)(2’OMeA)pG, m7(3’OMeG)(5’)ppp(5’)(2’OMeA)pG, orm7(3’OMeG)(5’)ppp('5)m6(2’OMeA)pG.
[0140] In preferred embodiments, the artificial RNA comprises the cap1 structure m7G(5’)ppp(5’)(2’OMeA)pG.Alternatively, the 5’-cap structure may be formed via enzymatic capping using capping enzymes (e.g. vaccinia virus capping enzymes and / or 2’-0 methyltransferases) to generate capO, cap1 or cap2 structures.
[0141] It is preferred that at least 80%, 85%, 90%, 95% of the artificial RNA molecules comprise a cap structure, preferably a cap1 structure, as determined by a capping assay (e.g. via an assay as described in cl.27 to 46 of W02015101416). In preferred embodiments, the artificial RNA comprises a 5’-terminal sequence comprising or consisting of a nucleic acid sequence being identical or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one AGGAGA, GGGAGA, GGGAAA, AGAAUA, AGAUUA, GAUGGG or GGGCG, or a fragment or variant of these, preferably AGGAGA. Such a 5’-terminal sequence element may comprise a binding site for an RNA polymerase. Preferably, the first nucleotide of said 5'-terminal sequence comprises a 2'0 methylation (2’OMeA or 2’OMeG).
[0142] Coding sequences:
[0143] According to preferred embodiments, the artificial RNA comprises at least one coding sequence (cds). In that context, any cds encoding at least one peptide or protein as defined herein, or fragments and variants thereof, may be understood as suitable cds, and may therefore be comprised in the artificial RNA of the invention.
[0144] In embodiments, the at least one coding sequence encodes at least one therapeutic peptide or protein.
[0145] In embodiments, the at least one therapeutic peptide or protein is selected from a CRISPR-associated endonuclease, an antibody, an intrabody, a receptor, a receptor agonist, a receptor antagonist, a binding protein, a chaperone, a transporter protein, an ion channel, a membrane protein, a secreted protein, a transcription factor, an enzyme, a peptide or protein hormone, a growth factor, a structural protein, a cytoplasmic protein, a cytoskeletal protein, a viral antigen or epitope, a bacterial antigen or epitope, a protozoan antigen or epitope, an allergen, an autoantigen, a tumor antigen or epitope, or fragments, variants, or combinations of any of these.
[0146] In preferred embodiments, the cds of the artificial RNA does not encode a Gnas protein.
[0147] Coding sequences encoding CRISPR-associated endonucleases:
[0148] Suitably, the at least one therapeutic peptide or protein is selected from a CRISPR-associated endonuclease, ex a fragment or variant thereof.
[0149] The term “CRISPR-associated endonuclease” refers to RNA-guided endonucleases that are part of a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system (and their homologs, variants, fragments or derivatives), which is used by prokaryotes to confer adaptive immunity against foreign DNA elements. CRISPR-associated proteins include, without limitation, Cas9, Cpf1 (Cas12), C2c1, C2c3, C2c2, Cas13, CasXand CasY. As used herein, the term “CRISPR-associated endonuclease” includes wild-type proteins as well as homologs, variants, fragments and derivatives thereof. Therefore, when referring to artificial nucleic acid molecules encoding Cas9, Cpf1 (Cas12), C2c1 , C2c3, and C2c2, Cas13, CasX and CasY, said artificial nucleic acid molecules may encode the respective wild-type proteins, or homologs, variants, fragments and derivatives thereof.In embodiments, the at least one coding sequence encodes a CRISPR-associated endonuclease as defined herein and additionally comprises at least one further effector domain.
[0150] An “effector domain” is to be understood as a protein moiety that confers an additional and / or new biological property or functionality. Effector domains may be selected based on their capability of conferring a (new or additional) biological function to the CRISPR-associated endonuclease, preferably without interfering with its ability to associate with a suitable guide RNA to specifically interact with a target DNA sequence. The new or additional biological function may be, for instance, transcriptional repression (inducing CRISPR interference, CRISPRi) or activation (inducing CRISPR activation, CRISPRa). Effector domains of interest may thus be selected from transcriptional repressor domains, including Kruppel associated box (KRAB) domains, MAX-interacting protein 1 (MXI1) domains, four concatenated mSin3 (SID4X) domains, or transcription activation domains, including herpes simplex VP16 activation domains (VP64 orVP160), nuclear factor-KB (NF-KB) transactivating subunit activation domain (p65AD). Such effector domain(s) can be fused to either amino (N-) or carboxyl (C-) termini of the CRISPR-associated endonuclease, or both. With suitable effector domains, transcription can also be regulated at the epigenetic level. Histone demethylase LSD1 removes the histone 3 Lys4 dimethylation (H3K4me2) mark from targeted distal enhancers, leading to transcription repression. The catalytic core of the histone acetyltransferase p300 (p300Core) can acetylate H3K27 (H3K27ac) at targeted proximal and distal enhancers, which leads to transcription activation. The new or additional biological functionality may, additionally or alternatively, be the recruitment of effector domains of interest. To that end, the effector domain may be a “recruiting domain”, preferably a protein-protein interaction domain or motif, such as WRPW (Trp-Arg-Pro-Trp) motifs. The new or additional biological function may, additionally or alternatively, be the recruitment of other entities of interest, such as RNAs. To that end, the effector domain may be selected from protein-RNA interaction domains, such as a cold shock domain (CSD).
[0151] A CRISPR-associated endonuclease comprising an effector domain thus include (a) CRISPR-associated endonuclease (or homologs, variants, fragments thereof) that are directly fused to (optionally via a suitable linker) effector domains capable of interacting with the target DNA sequence (or regulatory elements operably linked thereto) and (b) CRISPR-associated endonuclease (or homologs, variants, fragments thereof) that are fused to (optionally via a suitable linker) effector domains that recruit further effectors (domains, proteins or nucleic acids) of interest, that are, in turn, able to interact with the target DNA sequence (or regulatory elements operably linked thereto).
[0152] The at least one cds may encode at least one nuclear localization sequence (NLS). Said nucleic acid sequence encoding the NLS is preferably located within the cds (encoding the CRISPR-associated endonuclease). Therefore, the artificial RNA may comprise a cds encoding a CRISPR-associated endonuclease as defined herein, or a homolog, variant, fragment or derivative thereof, comprising at least one nuclear localization sequence (NLS).
[0153] A nuclear localization signal or sequence (NLS) is a short stretch of amino acids that mediates the transport of nuclear proteins into the nucleus. As CRISPR-associated endonuclease encoded by the artificial RNA are particularly envisaged for therapy and research in mammalian cells, they may be endowed with at least one NLS in order to enable their import into the nucleus where they can take their effects on genomic DNA. The NLS preferably interacts with nuclear pore complexes (NPCs) in the nuclear envelope, thereby facilitating transport of the CRISPR-associated endonuclease into the nucleus.According to embodiments, the artificial RNA further comprises at least one nucleic acid sequence encoding an NLS. The artificial nucleic acid RNA may thus encode 1 , 2, 3, 4, 5 or more NLSs, which are optionally selected from the NLS exemplified herein. Said NLS-encoding nucleic acid sequence is preferably located in the cds and is preferably fused to the nucleic acid sequence encoding the CRISPR-associated endonuclease, so that expression of said cds yields a CRISPR-associated endonuclease comprising said at least one NLS, preferably at its N-teiminus, C-terminus, or both. In other words, the artificial RNA may encode a CRISPR-associated endonuclease comprising at least one NLS, preferably at its N-terminus, C-terminus, or both.
[0154] Suitable NLS amino acid sequences comprise or consist of an amino acid sequence being identical to or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 381-382, 384, 426, 427; 10575, 11957-11964, 12021-14274 of published PCT patent application WQ2018172556, or a fragment or variant of any of these.
[0155] In preferred embodiments, the CRISPR-associated endonuclease comprises two or more NLSs, and these NLSs may for instance be selected from NLS2 (characterized by SEQ ID NO: 426 of WO2018172556) and NLS4 (characterized by SEQ ID NO: 427 of WO2018172556) or a functional variant or fragment of either or both of these nuclear localization signals.
[0156] A suitable coding sequence that encodes an NLS comprises or consists of a nucleic acid sequence being identical to, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 409-410; 1378-1379; 2538-2539; 3698-3699; 4858-4859, 6018-6019, 7178-7179, 8338-8339, 10551, 10581, 10584, 10587, 10590, 10593, 10596, or 11965-12020 of published PCT patent application WO2018172556, or a fragment or variant of any of these, preferably an N1 -methylpseudouridine (mlqj)-modified sequence version of any of these. In embodiments, the CRISPR-associated endonuclease is selected from Cas9, Cpf1 (Cas12), C2c1, C2c3, Cas13, CasX, or CasY.
[0157] "Cpf1 ” (“CRISPR from Prevotella and Francisella 1 ”) or “Cas12” refers to RNA-guided DNA endonucleases, which belong to the putative class 2 type V CRISPR-Cas systems, and homologs, variants, fragments and derivatives thereof. Cpf1 -encoding genes include the Francisella tularensis subsp. novicida (strain U112) cpf1 gene (NCBI Reference Sequence: NZ_CP009633.1 , “AW25_RS03035”) or homologs, variants or fragments thereof. Based on sequence analysis, Cpf1 contains only one detectable RuvC endonuclease domain, and a second putative novel nuclease (NUC) domain. Cpf1 proteins preferably associates with a crRNA to forming a Cpf1 :crRNA complex that is preferably capable of specifically interacting with a target DNA sequence. Cpf1 :crRNA complexes are preferably capable of efficiently cleaving target DNA proceeded by a short T-rich protospacer adjacent motif (PAM) located 5’ of the target DNA, and may introduce staggered DNA double stranded breaks with a 4 or 5-nt 5' overhang.
[0158] “Cas9” refers to RNA-guided Type II CRISPR-Cas DNA endonucleases, which may be encoded by the Streptococcus pyogenes serotype M1 cas9 gene (NCBI Reference Sequence: NC_002737.2, “SPy1046”; S. pyogenes) i.e. spCas9, or a homolog, variant or fragment thereof. Cas9 can preferably be recruited by a guide RNA (gRNA) to cleave, site- specifically, a target DNA sequence using two distinct endonuclease domains (HNH and RuvC / RNase H-like domains), one for each strand of the DNA's double helix. RuvC and HNH together produce double-stranded breaks (DSBs) andcan separately produce single-stranded breaks. Cas9 is preferably capable of specifically recognizing (and preferably binding to) a protospacer adjacent motif (PAM) juxtaposed to the target DNA sequence. The PAM is typically located 3’ of the target DNA any may comprise or consist of the three-nucleotide sequence NGG. It is typically recognized by the PAM-interacting domain (PI domain) located near the C-terminal end of Cas9.
[0159] Suitable Cas13, CasX and CasY proteins that may be encoded by the cds of the artificial RNA are provided under SEQ ID NO: 10893-10925; 10926-10998 of published PCT patent application WO2018172556 (Cas13 i.e. WP15770004, WP18451595, WP21744063, WP21746774, ERK53440, WP31473346, CVRQ01000008, CRZ35554, WP22785443, WP36091002, WP12985477, WP13443710, ETD76934, WP38617242, WP2664492, WP4343973, WP44065294, ADAR2DD, WP47447901, ERI81700, WP34542281, WP13997271, WP41989581, WP47431796, WP14084666, WP60381855, WP14165541, WP63744070, WP65213424, WP45968377, EHO06562, WP6261414, EKB06014, WP58700060, WP13446107, WP44218239, WP12458151, ERJ81987, ERJ65637, WP21665475, WP61156637, WP23846767, ERJ87335, WP5873511 , WP39445055, WP52912312, WP53444417, WP12458414, WP39417390, EOA10535, WP61156470, WP13816155, WP5874195, WP39437199, WP39419792, WP39431778, WP46201018, WP39442171, WP39426176, WP39418912, WP39434803, WP39428968, WP25000926, EFU31981, WP4343581, WP36884929, BAU18623, AFJ07523, WP14708441, WP36860899, WP61868553, KJJ86756, EGQ18444, EKY00089, WP36929175, WP7412163, WP44072147, WP42518169, WP44074780, WP15024765, WP49354263, WP4919755, WP64970887, WP61710138); 11002; 11003 (CasX i.e. OGP07438, OHB99618); and 11004-11010 (CasY i.e. OJI08769, OGY82221, OJI06454, APG80656, OJI07455, OJI09436, PIP58309).
[0160] In embodiments, the CRISPR-associated endonuclease comprises or consists of an amino acid sequence being identical to or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 428-1377, 10576-10577, 10893-11010, 14294-14321 of published PCT patent application WO2018172556, or a fragment or variant of any of these.
[0161] In some embodiments, the CRISPR-associated endonuclease is Cpf1. Suitable amino acid sequences of Cpf1 that comprise are provided in Table 3 of WO2018172556, Table 3, and the respective SEQ ID NOs disclosed therein, herewith incorporated by reference.
[0162] In preferred embodiments, the CRISPR-associated endonuclease is Cas 9.
[0163] Accordingly, in embodiments, the CRISPR-associated endonuclease is Cas9 and comprises or consists of an amino acid sequence being identical to or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 428-1345, 1362-1375, 10999-11001 of published PCT patent application WO2018172556, or a fragment or variant of any of these. Further details regarding suitable amino acid sequences of Cas9 are provided in T able 2 of WO2018172556, T able 2, and the respective SEQ ID NOs disclosed therein, herewith incorporated by reference.
[0164] In preferred embodiments, the encoded CRISPR-associated endonuclease is Cas9 and comprises or consists of an amino acid sequence being identical to or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 617 or 618, or a fragment or variant of any of these.Suitably, the encoded CRISPR-associated endonuclease is Cas9 and comprises a C-terminal and an N-terminal NLS sequence, preferably according to the following design: NLS2 - Cas9 - NLS4. Suitable amino acid sequences of Cas9 that comprise NLS sequences are provided in Table 2a and Table 2b of WO2018172556, Table 2a and 2b, and the respective SEQ ID NOs disclosed therein, herewith incorporated by reference.
[0165] In particularly preferred embodiments, the encoded CRISPR-associated endonuclease comprises or consists of an amino acid sequence being identical to or at least 80%, 85% 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 617, or a fragment or variant thereof.
[0166] In embodiments, the at least one coding sequence is a codon modified coding sequence. Suitably, the amino acid sequence encoded by the at least one codon modified cds has not been modified compared to the amino acid sequence encoded by a corresponding wild type or reference cds.
[0167] The term “codon modified cds” as used herein relates to a cds that differs in at least one codon compared to the corresponding wild type or reference cds. Suitably, a codon modified cds shows improved resistance to in vivo degradation and / or improved stability in vivo, and / or improved translatability in vivo. Codon modifications make use of the degeneracy of the genetic code wherein multiple codons can encode the same amino acid and may therefore be used interchangeably to optimize / modify the cds for in vivo applications.
[0168] In embodiments, the at least one cds is a codon modified cds, wherein the codon modified cds is selected from a C maximized cds (as further defined in WO2021239880 [p.122, lines 33 to 39] which is hereby incorporated by reference); a CAI maximized cds (as further defined in WO2021239880 [p.123, lines 33 to 44] which is hereby incorporated by reference); a human codon usage adapted cds (as further defined in WO2021239880 [p.123, lines 7 to 17] which is hereby incorporated by reference); a G / C content modified cds (as further defined in WO2021239880 [p.123, lines 19 to 31] which is hereby incorporated by reference); a G / C optimized cds (“opt1”); or any combination thereof.
[0169] In preferred embodiments, the codon modified cds is a G / C optimized coding sequence.
[0170] In preferred embodiments, the G / C content of the at least one cds is increased by at least 10%, 15%, or 20% compared to the G / C content of the corresponding wild type or reference cds.
[0171] In embodiments, the codon modified coding sequence is a G / C optimized coding sequence, preferably wherein the at feast one coding sequence has a G / C content of at feast about 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, suitably at least about 59%, 60%, 61%. In preferred embodiments, the at least one coding sequence has a G / C content of about 62%.
[0172] In embodiments, the at least one coding sequence encodes a CRISPR-associated endonuclease and comprises or consists of a nucleic acid sequence being identical to or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NO: 411 , 412, 1380-2329, 2540-3489, 3700-4649, 4860-5809, 6020- 6969, 7180-8129, 8340-9289, 10395-10401, 10551, 10552, 10579, 10580, 10582, 10583, 10585, 10586, 10588, 10589, 10591, 10592, 10594, 10595, 10597, 10598, 11011-11956, 14322-14520 of published PCT patent application WO2018172556, or a fragment or variant of any of these, preferably an N1 -methylpseudouridine (ml i )-modified sequence version of any of these.In preferred embodiments, the at least one coding sequence encodes a Cas 9 endonuclease.
[0173] Accordingly, in embodiments, the at least one coding sequence encodes a Cas9 endonuclease and comprises or consists of a nucleic acid sequence being identical to or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NO: 411 , 412, 1380-2297, 2314-2327, 2540-3457, 3474-3487, 3700- 4617, 4634-4647, 4860-5777, 5794-5807, 6020-6937, 6954-6967, 7180-8097, 8114-8127, 8340-9257, 9274-9287, 11709-11711, 11827-11829, 11591-11593, 11473-11475, 11355-11357, 11237-11239, 11117-11119, 11945-11947, 14518-14520 of published PCT patent application WO2018172556, or a fragment or variant of any of these, preferably an N1-methylpseudouridine (ml ip)-modified sequence version of any of these.
[0174] In preferred embodiments, the at least one coding sequence encodes a CRISPR-associated endonuclease and comprises or consists of a nucleic acid sequence being identical to or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 611-616, or a fragment or variant of any of these. In more preferred embodiments, the at least one cds encodes Cas9 and comprises or consists of a N1 -methylpseudouridine (m1ip) modified nucleic acid sequence being identical to or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 615, or a fragment or variant thereof.
[0175] In particularly embodiments, the at least one cds encodes Cas9 (NLS2-Cas9-NLS4) and comprises or consists of a N1-methylpseudouridine (ml i ) modified nucleic acid sequence being identical to or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NO: 612, or a fragment or variant thereof. In embodiments, the at least one coding sequence has a length of, with increasing preference, at least 3000 nucleotides, 3500 nucleotides, 4000 nucleotides, 4500 nucleotides, or more than 4500 nucleotides.
[0176] Further RNA features:
[0177] In embodiments, the artificial RNA comprises at least one miRNA binding site, a Kozak sequence, and / or at least one poly(C)sequence.
[0178] In preferred embodiments, the artificial RNA comprises a ribosome binding site, also referred to as “Kozak sequence”, that is identical to or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 15, or sequences GCCGCCACC, GCCACC, ACC, preferably ACC (RNA).
[0179] In embodiments, the coding sequence is terminated with more than one stop codon, preferably 2 or 3 stop axions. In preferred embodiments, the artificial RNA may be any type of RNA that comprises a coding sequence as defined herein and may include any type of single stranded RNA, double stranded RNA, linear RNA, and circular RNA.
[0180] In embodiments, the artificial RNA is an mRNA, a circRNA, a replicon RNA, a self-replicating RNA, or viral RNA In embodiments, the artificial RNA is a circular RNA. A “circular RNA” (circRNAs) is an RNA connected to form a circle and therefore does not comprise a 3’ or 5’ terminus. Said circRNA comprises at least one cds as defined herein.
[0181] CircRNA construct designs can be taken from WO2023073228, claims 1 to 51 , hereby incorporated by reference.In other embodiments, the artificial RNA is a replicon RNA or self-replicating RNA. Such constructs may encode replicase elements derived from e.g. alphaviruses (e.g. SFV, SIN, VEE, or RRV) and a cds as defined herein.
[0182] In particularly preferred embodiments, the artificial RNA of the invention is an mRNA
[0183] An mRNA is preferred to provide the encoded peptide or protein as defined herein because mRNA allows for regulated dosage, transient expression, complete degradation of the mRNA after protein synthesis, and does not pose the risk of insertional mutations. Preferably, the mRNA is non-replicative.
[0184] In embodiments, the artificial RNA comprises, with increasing preference, 3500 to 10000 nucleotides, 3500 to 7500 nucleotides, 3500 to 5000 nucleotides.
[0185] Advantageously, the artificial RNA of the invention that comprises Gnas-min as defined herein can be produced at high quality, even in embodiments where the artificial RNA comprises large coding sequences (e.g. in embodiments where the cds has a length of at least 3500 nucleotides, 4000 nucleotides, 4500 nucleotides) which leads so very long RNA sequences (e.g. in embodiments where the artificial RNA also comprises a 5’ UTR sequence element as defined herein and a 3’ Poly(A) and / or a histone-stem loop). Therefore, minimizing the Gnas UTR to arrive at Gnas-min as defined herein has advantages when it comes to manufacturability of the artificial RNA, in particular in embodiments where the artificial RNA comprises 3500 to 10000 nucleotides, 3500 to 7500 nucleotides, preferably 3500 to 5000 nucleotides. In preferred embodiments, the artificial RNA is an in vitro transcribed RNA, preferably an in vitro transcribed mRNA. Accordingly, the artificial RNA is preferably produced using RNA in vitro transcription. The term “RNA in vitro transcription” (IVT) relates to a process wherein RNA is synthesized in a cell-free system in vitro. In IVT, the RNA is obtained by transcribing a DNA template in the presence of a DNA-dependent RNA polymerase (e.g. T7, SP6), ribonucleotide triphosphates (NTPs, and optionally modified NTPs) and optionally, a cap analog, in an appropriate buffer (e.g. comprising MgCI2). Advantageously, an RNA in vitro transcription to generate the artificial RNA of the invention comprising Gnas-min produces less by-products and impurities compared to an RNA in vitro transcription to generate a reference RNA that comprises a full-length Gnas 3’ UTR element
[0186] In preferred embodiments, the artificial RNA is a purified RNA, preferably a purified mRNA.
[0187] The term “purified RNA” refers to RNA which has a higher purity after certain purification steps than the starting material. Typical impurities comprise peptides, proteins, spermidine, RNA fragments, dsRNA, free nucleotides, DNA, etc. It is desirable for the “degree of RNA purity” to be as close as possible to 100%. Preferably, a “purified RNA” has a degree of purity of more than 75%, 80%, 85%, 90%, or 95%. The degree of purity may be determined by an analytical HPLC. In embodiments, the artificial RNA has been purified by (RP)HPLC, AEX, size exclusion chromatography (SEC), hydroxyapatite chromatography, tangential flow filtration (IFF), filtration, precipitation, core-bead flow through chromatography, oligo(dT) purification, cellulose-based purification, or combinations thereof. Preferably, the artificial RNA has been purified by (RP)HPLC (suitably as described in W02008077592), TFF (suitably as described in WO2016193206), oligo d(T) purification, or combinations thereof.In particularly preferred embodiments, the artificial RNA has been purified by at least one step of TFF.
[0188] In embodiments, the artificial RNA has an integrity of at least 60%, 70%, 80%, 90%. The term “RNA integrity” describes whether the complete RNA sequence is present. In preferred embodiments, the artificial RNA has an integrity that is at least 5%, 10%, 15% higher than the integrity value of a reference RNA that comprises a full-length Gnas 3’ UTR element RNA integrity can be determined by RP-HPLC and may be based on determining the area under the peak of the expected full-length RNA in a chromatogram.
[0189] Preferred structure of the artificial RNA:
[0190] In preferred embodiments, the invention provides an artificial RNA that comprises (i) at least one coding sequence and (ii) at least one 3’ untranslated region (3’ UTR) comprising at least one minimized Gnas 3’ UTR sequence element (Gnas-min), wherein Gnas-min preferably consists of a section of 70 to 150 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or taken from a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0191] The artificial RNA may additionally comprise further structural elements as defined herein, for example at least one 5’ UTR sequence element as defined herein, a 5’ cap structure as defined herein, a certain coding sequence as defined herein (e.g. encoding a CRISPR-associated endonuclease), certain 3’ terminal elements such as at least one Poly(A) sequence as defined herein, or at least one hsl as defined herein, etc. Further, the artificial RNA of the invention may suitably comprise at least one modified nucleotide as defined herein.
[0192] Preferred structures of the artificial RNA of the invention are described in the following.
[0193] In embodiments, the artificial RNA, preferably the mRNA, comprises in 5’ to 3’ direction
[0194] a) a Cap structure, preferably as defined in section “Cap structures”;
[0195] b) at least one 5’ untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element as defined in section “5’ UTR sequence element';
[0196] c) at least one coding sequence, preferably as defined in section “coding sequences”;
[0197] d) at least one 3’ untranslated region (3’ UTR) comprising a minimized Gnas 3' UTR sequence element (Gnas- min) as defined in section “Minimized Gnas 3’ UTR sequence element';
[0198] e) optionally, at least on hsl as defined in section “Histone stem-loop sequences”;
[0199] f) at least one poly(A) sequence, preferably as defined in section “Poly(N)sequences”;
[0200] wherein the artificial RNA preferably comprises at least one modified nucleotide as defined in section “modified nucleotides”.
[0201] In preferred embodiments, the artificial RNA, preferably the mRNA, comprises in 5’ to 3’ direction
[0202] a) a Cap structure, preferably as defined in section “Cap structures”;
[0203] b) at least one 5’ untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element preferably as defined in section “5’ UTR sequence element”;
[0204] c) at least one coding sequence preferably as defined in section “coding sequences encoding CRISPR- associated endonucleases”, more preferably comprising or consisting of a nucleic acid sequence encoding aCRISPR-associated endonuclease, wherein the CRISPR-associated endonuclease comprises or consists of an amino acid sequence being identical to, or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 428-1377, 10576-10577, 10893-11010, 14294-14321 of published PCT patent application WO2018172556, or a fragment or variant of any of these, preferably wherein the CRISPR-associated endonuclease comprises or consists of an amino acid sequence being identical to, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 617 or 618;
[0205] d) at least one 3’ untranslated region (3’ UTR) comprising a minimized Gnas 3' UTR sequence element (Gnas- min) as defined in section “Minimized Gnas 3’ UTR sequence element';
[0206] e) optionally, at least on hsl as defined in section “Histone stem-loop sequences”;
[0207] f) at least one poly(A) sequence, preferably as defined in section “Poly(N)sequences";
[0208] wherein the artificial RNA preferably comprises at least one modified nucleotide as defined in section “modified nucleotides’’, preferably wherein the at least one modified nucleotide is N1-methylpseudouridine.
[0209] In more preferred embodiments, the artificial RNA, preferably the mRNA, comprises in 5’ to 3’ direction
[0210] a) a Cap1 structure, preferably as defined in section “Cap structures”;
[0211] b) at least one 5’ untranslated region (5 UTR) comprising at least one 5’ UTR sequence element selected or derived from HSD17B4 comprising or consisting of a nucleic acid sequence being identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 24-26, preferably SEQ ID NO: 25.
[0212] c) at least one coding sequence preferably as defined in section “coding sequences encoding CRISPR- associated endonucleases”, more preferably comprising or consisting of a nucleic acid sequence encoding a CRISPR-associated endonuclease, wherein the CRISPR-associated endonuclease comprises or consists of an amino acid sequence being identical to, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 428-1377, 10576-10577, 10893-11010, 14294-14321 of published PCT patent application WO2018172556, or a fragment or variant of any of these, preferably wherein the CRISPR-associated endonuclease comprises or consists of an amino acid sequence being identical to, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 617 or 618, or a fragment or variant thereof;
[0213] d) at least one 3’ untranslated region (3’ UTR) comprising a minimized Gnas 3’ UTR sequence element (Gnas- min), wherein Gnas-min comprises or consists of a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 5-7, 53-607, preferably SEQ ID NO: 2;
[0214] e) optionally, at least on hsl comprising or consisting of a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 16;
[0215] f) at least one poly(A) sequence having about 100 A nucleotides, preferably located directly at the 3’ terminus of the artificial RNA, thereby representing the 3’ terminal sequence end of the artificial RNA;
[0216] wherein the artificial RNA comprises at least one modified nucleotide as defined in section “modified nucleotides”, preferably wherein 100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with N1- methylpseudouridine.In even more preferred embodiments, the artificial RNA, preferably the mRNA, comprises in 5’ to 3’ direction a) a Cap1 structure as defined in section “Cap structures”;
[0217] b) at least one 5’ untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element from HSD17B4 comprising or consisting of a nucleic acid sequence SEQ ID NO: 25;
[0218] c) at least one coding sequence, preferably as defined in section “coding sequences encoding CRISPR- associated endonucleases", more preferably wherein the CRISPR-associated endonuclease comprises or consists of an amino acid sequence being identical to, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 617 or 618, or a fragment or variant thereof;
[0219] d) at least one 3’ untranslated region (3’ UTR) comprising a minimized Gnas 3’ UTR sequence element (Gnas- min), wherein Gnas-min consists of a nucleic acid sequence SEQ ID NO: 2;
[0220] e) optionally, at least on hsl comprising or consisting of a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 16;
[0221] f) at least one poly(A) sequence having about 100 A nucleotides, preferably located directly at the 3’ terminus of the artificial RNA, thereby representing the 3’ terminal sequence end of the artificial RNA;
[0222] wherein 100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with N1-methylpseudouridine.
[0223] In particularly preferred embodiments, the artificial RNA, preferably the mRNA, comprises in 5’ to 3’ direction a) a Cap1 structure as defined in section “Cap structures”;
[0224] b) at least one 5’ untranslated region (5' UTR) comprising at least one 5’ UTR sequence element from HSD17B4 comprising or consisting of a nucleic acid sequence SEQ ID NO: 25;
[0225] c) at least one coding sequence comprising or consisting of a nucleic acid sequence encoding a CRISPR- associated endonuclease, more preferably comprising or consisting of a nucleic acid sequence being identical to, or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 612 or 615, or a fragment or variant of any of these, preferably SEQ ID NO: 612;
[0226] d) at least one 3’ untranslated region (3’ UTR) comprising a minimized Gnas 3’ UTR sequence element (Gnas- min), wherein Gnas-min consists of a nucleic acid sequence SEQ ID NO: 2;
[0227] e) at least on hsl comprising or consisting of a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 16;
[0228] f) at least one poly(A) sequence having about 100 A nucleotides located directly at the 3’ terminus of the artificial RNA, thereby representing the 3’ terminal sequence end of the artificial RNA;
[0229] wherein 100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with N1-methylpseudouridine.
[0230] In embodiments, the at least one artificial RNA of the invention comprises a 5’ portion (e.g. comprising a 5’ UTR sequence element as defined herein), a central portion (comprising a coding sequence as defined herein), and a 3' portion (comprising Gnas-min and further elements such as a poly(A)sequence). In the context of the invention, the artificial RNA preferably contains the 5’ portion, the central portion, and the 3’ portion in this order.
[0231] In embodiments, the artificial RNA, preferably the mRNA, comprisesa 5’ portion comprising or consisting of a nucleic acid sequence identical to, or at feast 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid sequence according to SEQ ID NOs: 9-11 ; a central portion comprising a cds preferably as defined herein, more preferably comprising or consisting of a nucleic add sequence encoding a CRISPR-associated endonuclease;
[0232] a 3’ portion comprising Gnas-min, the 3’ terminal sequence comprising or consisting of a nucleic add sequence identical to or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic add sequence according to SEQ ID NOs: 12-14.
[0233] In preferred embodiments, the artificial RNA, preferably the mRNA, comprises
[0234] a 5' portion comprising or consisting of a nucleic acid sequence identical to, or at feast 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic acid sequence according to SEQ ID NOs: 10; a central portion comprising a cds preferably as defined herein, more preferably comprising or consisting of a nucleic add sequence encoding a CRISPR-associated endonuclease;
[0235] a 3’ portion comprising Gnas-min, the 3’ terminal sequence region comprising or consisting of a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the nucleic add sequence according to SEQ ID NOs: 13.
[0236] In particularly preferred embodiments, the artificial RNA, preferably the mRNA, comprises
[0237] a 5’ portion comprising or consisting of a nucleic acid sequence identical to SEQ ID NOs: 10;
[0238] a central portion comprising a cds preferably as defined herein, more preferably comprising or consisting of a nucleic add sequence encoding a CRISPR-associated endonuclease;
[0239] a 3’ portion comprising or consisting of a nucleic acid sequence identical to SEQ ID NOs: 13.
[0240] In preferred embodiments in this context, the 5’ portion comprises a 5’ terminal Cap structure, preferably a Cap1. In preferred embodiments, 100% of the uracil in the nucleic acid sequence of the 5’ portion, the central portion, and the 3’ portion are substituted with pseudouridine or N1 -methylpseudouridine, preferably with N1-methylpseudouridine.
[0241] Preferred RNA / mRNA sequences:
[0242] In embodiments, the artificial RNA comprises or consists of a nucleic acid sequence which is identical to, or at feast 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 608-610, 619-654, 662-667, or a fragment or variant of any of these sequences.
[0243] In preferred embodiments, the artificial RNA comprises or consists of an N1 -methylpseudouridine modified nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 609, 631-642, 662-667.
[0244] In alternative embodiments, the artificial RNA comprises or consists of a pseudouridine modified nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 610, 643-654.In more preferred embodiments, the artificial RNA comprises or consists of an N1-methylpseudouridine modified nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 609.
[0245] In even more preferred embodiments, the artificial RNA comprises or consists of an N1-methylpseudouridine modified nucleic acid sequence identical to SEQ ID NOs: 609.
[0246] In particularly preferred embodiments, the artificial RNA consists of an N1 -methylpseudouridine modified nucleic acid sequence identical to SEQ ID NOs: 609, and wherein the artificial RNA comprises a 5’ cap1 structure.
[0247] Gnas-min improves manufacturing of an artificial RNA:
[0248] Gnas-min confers some advantageous properties when it comes to the manufacturability of the artificial RNA Typically, an RNA is produced in a process called “RNA in vitro transcription”. This in vitro synthesis process typically generates unwanted by-products such as abortive RNA sequences, double stranded RNA sequences, or other byproducts. However, it is desired, especially in the context of large-scale manufacturing of an RNA medicament, that the production process produces only small amounts of by-products and produces large quantities of intact, full-length RNA. As unexpectedly observed by the inventors, minimizing the 3' Gnas UTR as defied herein, in other words reducing the length of the full length Gnas 3’ UTR from e.g. 353 nucleotides to a smaller size such as to 70 to 150 nucleotides, improved the impurity profile of the artificial RNA after RNA in vitro transcription. This is especially important in the context of producing larger RNA (e.g. RNA encoding larger proteins such as CRISPR-associated endonucleases), as producing larger RNA is typically more challenging (more impurities, more dsRNA, etc.). Even more surprisingly, the incorporation of Gnas-min (instead of the full length Gnas) had no negative impact on the translation efficiency of the encoded peptide or protein upon administration of the artificial RNA to a cell or a subject.
[0249] Furthermore, advantageously, an artificial RNA that comprises a combination of a HSD17B45’ UTR sequence and a Gnas-min 3’-UTR sequence (“gn1 ”) can also be produced at high quality, even in embodiments where the artificial RNA comprises large coding sequences which leads to very long RNA sequences.
[0250] The advantage on improved manufacturability is mostly pronounced in embodiments where the artificial RNA comprises 3500 to 10000 nucleotides, 3500 to 7500 nucleotides, preferably 3500 to 5000 nucleotides.
[0251] Accordingly, in preferred embodiments, the content of impurities contained in a preparation of the artificial RNA is reduced during or after manufacturing compared to the content of impurities contained in a preparation of a reference RNA that comprises a full length Gnas 3’ UTR sequence.
[0252] In embodiments, the dsRNA content contained in a preparation of the artificial RNA (comprising Gnas-min) is decreased during or after manufacturing compared to the dsRNA content contained in a preparation of a reference RNA that comprises a full length Gnas 3’ UTR sequence. The dsRNA content can be determined by dsRNA Elisa using dsRNA- specific antibodies.In embodiments, the RNA integrity of the artificial RNA (comprising Gnas-min) is increased during or after manufacturing compared to the RNA integrity of a reference RNA that comprises a full length Gnas 3’ UTR sequence. The RNA integrity can be determined by RP-HPLC and may be based on determining the area under the peak of the expected full-length RNA in a chromatogram.
[0253] During manufacturing typically means during the process of RNA in vitro transcription before subjecting the produced RNA preparation to purification steps. After manufacturing typically means after the process of RNA in vitro transcription and after subjecting the produced RNA preparation to purification steps.
[0254] A “reference RNA” in this context is essentially identical to the artificial RNA, with the exception that the reference RNA comprises the full length Gnas 3’ UTR instead of Gnas-min. Accordingly, for sake of comparability, the “reference RNA” comprises, if present, an identical cds, an identical Cap structure, an identical poly(A), an identical 5’ UTR, an identical hsl, an identical modification pattern - however, as defined above, the reference RNA comprises the full length Gnas 3’ UTR (SEQ ID NO: 8), whereas the artificial RNA of the invention comprises Gnas-min as defined herein.
[0255] Gnas-min improves translation efficiency of an RNA
[0256] Gnas-min confers some advantageous properties when it comes to translation efficiency of an RNA canprising Gnas-min. Gnas-min confers some advantageous properties when it comes to translation efficiency of an RNA comprising Gnas-min and additionally comprising modified nucleotides.
[0257] As unexpectedly observed by the inventors, minimizing the 3’ Gnas UTR as defied herein, in other words reducing the length of the full length Gnas 3’ UTR from e.g. 353 nucleotides to a smaller size, preferably to 70 to 150 nudeotides, improved the translation efficiency of an RNA (containing Gnas-min) compared with a reference RNA construct comprising the full length Gnas 3’UTR.
[0258] Accordingly, in embodiments, when administered to a cell or subject, the translation efficiency of the artificial RNA (comprising Gnas-min) that is increased compared to the translation efficiency of a reference RNA that comprises a full length Gnas 3’ UTR sequence.
[0259] Even more surprisingly, Gnas-min also allowed for a modification with e.g. modified nucleotides without causing a translational loss / a reduction in translation efficiency. Translation efficiency is very often negatively affected by chemical modification of the 3’ UTR because it is believed that protein interaction is reduced by chemical modifications, especially in A / U rich regions. As the 3’ UTR region has a paramount importance for regulating the in vivo translation of an RNA into a protein, hampering protein interactions with e.g. factors that impact RNA stability and / or translation is obviously not desired.
[0260] In particular, the combination of a HSD17B45’ UTR sequence and a Gnas-min 3-UTR sequence (“gn1”) allows for the use of modified nucleotides (e.g. modified uridine nucleotide such as, e.g., pseudouridine (ip) or N1 -methylpseudouridine (ml ip)) without a translational loss / a reduction in translation efficiency.
[0261] Accordingly, in embodiments, when administered to a cell or subject, the translation efficiency of the artificial RNA (comprising Gnas-min) that contains at least one modified nucleotide, preferably N1 -methylpseudouridine, is increasedcompared to the translation efficiency of a reference RNA that comprises a full length Gnas 3’ UTR sequence and that contains at least one modified nucleotide, preferably N1-methylpseudouridine.
[0262] A “reference RNA” in this context is essentially identical to the artificial RNA, with the exception that the reference RNA canprises the full length Gnas 3’ UTR instead of Gnas-min. Accordingly, for sake of comparability, the “reference RNA” in this context comprises, if present, an identical cds, an identical Cap structure, an identical poly(A), an identical 5’ UTR, an identical hsl, an identical modification pattern - however, as defined above, the reference RNA comprises the full length Gnas 3’ UTR (SEQ ID NO: 8), whereas the artificial RNA of the invention comprises Gnas-min as defined herein. In embodiments, the translation efficiency of the artificial RNA that comprises Gnas-min that contains at least one modified nucleotide, preferably N1 -methylpseudouridine (e.g. an artificial RNA comprising SEQ ID NO: 2), is essentially equal compared with the translation efficiency of the artificial RNA that comprises Gnas-min and does not contain at least one modified nucleotide (e.g. an artificial RNA comprising SEQ ID NO: 1).
[0263] In embodiments, unwanted immune stimulation caused by a modified artificial RNA (comprising Gnas-min), in particular the induction of INFa, is reduced compared to a modified reference RNA comprises the full length Gnas 3’ UTR.
[0264] 2: Pharmaceutical composition:
[0265] In a second aspect, the invention provides a composition comprising at least one artificial RNA of the first aspect. It should be noted that specific features and embodiments described in the context of the first aspect are likewise applicable to the second aspect.
[0266] A “composition comprising at least one artificial RNA” refers to any type of composition in which the specified at least one artificial RNA is incorporated, optionally along with any further constituents, usually with at least one pharmaceutically acceptable carrier or excipient. The composition may be a dry composition such as a powder, a granule, or a solid lyophilized form. Alternatively, the composition may be in liquid form, and each constituent may be independently incorporated in dissolved or dispersed (e.g. suspended or emulsified) form. In preferred embodiments, the composition is a pharmaceutical composition.
[0267] In embodiments, the composition comprises at least one artificial RNA as defined in the first aspect, preferably an artificial RNA comprising (i) at least one coding sequence and (ii) at least one 3’ untranslated region (3’ UTR) comprising at least one minimized Gnas 3’ UTR sequence element (Gnas-min) as defined herein.
[0268] In embodiments, the composition comprises at least one artificial RNA comprising at least one coding sequence as defined in sections “coding sequences encoding CRISPR-associated endonucleases” of the first aspect.
[0269] In embodiments, the composition comprises at least one artificial RNA that comprises in 5’ to 3’ direction
[0270] a) a Cap structure, preferably as defined in section “Cap structures”;
[0271] b) at least one 5’ untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element as defined in section “5’ UTR sequence element’;
[0272] c) at least one coding sequence, preferably as defined in section “coding sequences”;d) at least one 3’ untranslated region (3’ UTR) comprising a minimized Gnas 3’ UTR sequence element (Gnas- min) as defined in section “Minimized Gnas 3’ UTR sequence element';
[0273] e) optionally, at least on hsl as defined in section “Histone stem-loop sequences”;
[0274] I) at least one poly(A) sequence, preferably as defined in section “Poly(N)sequences”;
[0275] wherein the artificial RNA preferably comprises at least one modified nucleotide as defined in section “modified nucleotides".
[0276] In embodiments, the composition comprises at least one artificial RNA, preferably at feast on mRNA, that comprises a structure as defined in section “Preferred structure of the artificial RNA” of the first aspect.
[0277] In embodiments, the composition comprises at least one artificial RNA that comprises or consists of a nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 608-610, 619-654, 662-667, or a fragment or variant of any of these sequences. In preferred embodiments, the composition comprises at least one artificial RNA that comprises or consists of an N1 -methylpseudouridine modified nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 609, 631-642, 662-667. In alternative embodiments, the composition comprises at least one artificial RNA that comprises or consists of a pseudouridine modified nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 610, 643-654. In more preferred embodiments, the composition comprises at least one artificial RNA that comprises or consists of an N1-methylpseudouridine modified nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 609. In even more preferred embodiments, the composition comprises at least one artificial RNA that comprises or consists of an N1-methylpseudouridine modified nucleic acid sequence identical to SEQ ID NOs: 609. In particularly preferred embodiments, the composition comprises at least one artificial RNA that consists of an N1 -methylpseudouridine modified nucleic acid sequence identical to SEQ ID NOs: 609, and wherein the artificial RNA comprises a 5' cap1. In embodiments, the at least one artificial RNA is formulated with at least one cationic or polycationic compound. The term “cationic” means that the respective structure, compound, group, or atom bears a positive charge, either permanently or not permanently, e.g. in response to certain conditions such as pH. The terms “cationic”, “catbnisable”, and “permanently cationic” as used herein must be understood as defined in WO2023 / 031394 [p.12, line 32 to p.13, line 16]. The term “polycation'ic” means that the respective structure, compound, group, or atom bears a plurality of positive charges. The term as used herein must be understood as defined in WO2021 / 156267 [p.88, line 12 to p.89, line 22], In that context, the artificial RNA is preferably complexed or associated with or at least partially complexed or partially associated with one or more cationic or polycationic compound. In embodiments, the at least one cationic or polycationic compound is selected from a cationic or polycationic polymer, a cationic or polycationic polysaccharide, a cationic or polycationic lipid, a cationic or polycationic protein, a cationic or polycationic peptide, or any combinations thereof.Preferably, the at least one cationic or polycationic compound is a cationic or polycationic lipid. Cationic or polycationic compounds being suitable in the context of the invention may be selected from p.88, line 24 to p.89, line 10 in WO2021 / 156267, the respective cationic or polycationic compounds herewith incorporated by reference.
[0278] Lipid-based carriers:
[0279] In embodiments, the at least one artificial RNA contained in the composition is formulated in a lipid-based carrier.
[0280] The term “lipid-based carrier” as used herein encompasses lipid-based delivery systems for RNA that comprise a lipid component. A lipid-based carrier may additionally comprise other components suitable for formulating an RNA including a cationic or polycationic polymer, polysaccharide, protein, and / or peptide.
[0281] The at least one artificial RNA of the composition may completely or partially be incorporated or encapsulated in a lipid-based carrier, wherein the artificial RNA may be located in the interior space of the lipid-based carrier, within the lipid layer / membrane of the lipid-based carrier or associated with the exterior surface of the lipid-based carrier. The incorporation of RNA into lipid-based carriers may be referred to as “encapsulation”.
[0282] The term “encapsulation” as used herein refers to the essentially stable combination of RNA with one or more lipids into larger complexes or assemblies such as lipid-based carriers, preferably without covalent binding of the nucleic acid. The encapsulated RNA may be completely or partially located in the interior of the lipid-based carrier (e.g. the lipid portion and / or an interior space) and / or within the lipid layer / membrane of the lipid-based carriers.
[0283] In embodiments, the lipid-based carrier is selected from a lipid nanoparticle (LNP), a liposome, a lipoplex, a solid lipid nanoparticle, a lipo-polyplex, and / or a nanoliposome.
[0284] In preferred embodiments, the lipid-based carrier is a lipid nanoparticle (LNP). Accordingly, in preferred embodiments, the pharmaceutical composition comprises the at least one artificial RNA formulated in a lipid nanoparticle (LNP). LNPs are microscopic lipid particles having a solid or partially solid core. In an LNP, the RNA may be encapsulated in the lipid portion of the LNP, enveloped by some or the entire lipid portion of the LNP. An LNP may comprise any lipid capable of forming a particle to which the RNA may be attached, or in which the RNA may be encapsulated.
[0285] Accordingly, in embodiments, the lipid-based carrier, preferably the LNP, comprises at least one or more lipids selected from at least one aggregation-reducing lipid, at least one cationic lipid or ionizable lipid, at least one neutral lipid or phospholipid, or at least one steroid or steroid analog, or any combinations thereof.
[0286] In preferred embodiments, the lipid-based carrier, preferably the LNP, comprises (i) at least one aggregation-reducing lipid, (ii) at least one cationic lipid or ionizable lipid, (iii) at least one neutral lipid or phospholipid, (iv) and at least one steroid or steroid analog.
[0287] In embodiments, the lipid-based carrier, preferably the LNP, comprises at least one aggregation reducing lipid or moiety. The term “aggregation reducing moiety” refers to a molecule comprising a moiety suitable of reducing or preventing aggregation of the lipid-based carrier, preferably the LNP. The term “aggregation reducing lipid” refers to a molecule comprising both a lipid portion and a moiety suitable of reducing or preventing aggregation of the lipid-based carrier. Under storage conditions or during formulation, the lipid-based carrier may undergo charge-induced aggregation, acondition which can be undesirable for its stability. Therefore, it can be desirable to include a compound or moiety which can reduce aggregation, e.g. by sterically stabilizing the lipid-based carriers. Such a steric stabilization may occur when a compound having a sterically bulky but uncharged moiety that shields or screens the charged portions of a lipid-based carrier from close approach to other lipid-based carrier. Stabilization of the lipid-based carrier, preferably the LNP, may be achieved by including lipids which may comprise a lipid bearing a sterically bulky group which, after formation of the lipid-based carrier, is preferably located on the exterior of the lipid-based carrier. Suitable aggregation reducing groups may include hydrophilic groups, e.g. monosialoganglioside GM1 , polyamide oligomers (PAO), or certain polymers, such as poly(oxyalkylenes), e.g., polyethylene glycol) or polypropylene glycol).
[0288] In embodiments, the aggregation reducing lipid is a polymer conjugated lipid.
[0289] Lipids comprising a polymer as aggregation reducing group are herein referred to as “polymer conjugated lipid”. The term “polymer conjugated lipid” refers to a molecule comprising both a lipid portion and a polymer portion, wherein the polymer is suitable of reducing or preventing aggregation of lipid-based carriers comprising the nucleic acid. A polymer has to be understood as a substance or material consisting of very large molecules, or macromolecules, composed of many repeating subunits. A suitable polymer in the context of the invention may be a hydrophilic polymer. An example of a polymer conjugated lipid is a PEGylated or PEG-conjugated lipid.
[0290] In embodiments, the polymer conjugated lipid is selected from a PEG-conjugated lipid or a PEG-free lipid.
[0291] In embodiments, the polymer conjugated lipid is a PEG-conjugated lipid. The average molecular weight of the PEG moiety in the PEG-conjugated lipid may range from 500 to 8,000 Daltons (e.g., from 1 ,000 to 4,000 Daltons). In one embodiment, the average molecular weight of the PEG moiety is about 2,000 Daltons. In embodiments, the PEG-conjugated lipid is selected or derived from 1 ,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000 DMG or DMG-PEG 2000), C10-PEG2K, or Cer8-PEG2K
[0292] In embodiments, the polymer conjugated lipid is selected or derived from formula (IV) of WO2018078053, preferably from formula (IVa) of WO2018078053. In that context, a preferred polymer-conjugated lipid is selected from ALC-0159 (2[(polyethyleneglycol)-2000]-N,N-ditetradecylacetamide).
[0293] In, the aggregation reducing lipid is selected from a PEG-free lipid, e.g. a PEG-free polymer conjugated lipid. Preferably, the aggregation reducing lipid is a PEG-free lipid that comprises a polymer different from PEG.
[0294] A PEG-free polymer conjugated lipid may be selected or derived from a “POZ-lipid”. In embodiments, the “POZ lipids” or respectively preferred polymer conjugated lipids are described in W02023031394, the full disclosure herewith incorporated by reference. In particular, the disclosure relating to polymer conjugated lipids as defined in any one of claims 1 to 8 ofWO2023031394 is herewith incorporated by reference. In embodiments, the polymer conjugated lipid is a PEG-free lipid selected from a POZ-lipid. In preferred embodiment in the context of POZ-lipids, the aggregationreducing lipid is selected or derived from PMOZ 1 , PMOZ 2, PMOZ 3, PMOZ 4, or PMOZ 5 of WO2023031394, the disclosure relating to PMOZ 1 , PMOZ 2, PMOZ 3, PMOZ 4, or PMOZ 5 herewith incorporated by reference Accordingly, in embodiments, the at least one aggregation-reducing lipid is selected or derived from DMG-PEG 2000, C10-PEG2K, Cer8-PEG2K, a POZ-lipid such as PMOZ4, or ALC-0159.In embodiments, the lipid-based carrier, preferably the LNP, comprise at least one cationic or ionizable lipid.
[0295] The at least one cationic or ionizable lipid may be cationisable or ionizable, i.e. it becomes protonated as the pH is lowered below the pK of the ionizable group of the lipid but is progressively more neutral at higher pH values. At pH values below the pK, the lipid is then able to associate with negatively charged nucleic acids. In certain embodiments, the cationic lipid comprises a zwitterionic lipid that assumes a positive charge on pH decrease.
[0296] In embodiments, the at least one cationic or ionizable lipid may cany a net positive charge at physiological pH.
[0297] Preferably the cationic or ionizable lipid comprises a quaternary nitrogen group or tertiary nitrogen group, most preferably a tertiary nitrogen group. Accordingly, the at least one cationic or ionizable lipid may be selected from an amino lipid. Preferably, the at least one cationic lipid or ionizable lipid is selected from an amino lipid, preferably wherein the amino lipid comprises a tertiary amine group.
[0298] In embodiments, the at least one cationic or ionizable lipid is selected from the lipids disclosed in WO2018078053 (i.e. lipids derived from formula I, II, and III of WO2018078053, or lipids as specified in claims 1 to 12), the disclosure of W02018078053 hereby incorporated by reference. In that context, lipids disclosed in Table 7 of WO2018078053 (e.g. lipids derived from formula 1-1 to 1-41), and lipids disclosed inTable8ofWQ2018078053 (e.g. lipids derived from formula 11-1 to II-36) may be suitably used in the context of the invention. Accordingly, formula 1-1 to formula 1-41 and formula 11-1 to formula II-36 of WO2018078053, and the specific disclosure relating thereto, are herewith incorporated by reference. In embodiments, the at least one cationic or ionizable lipid is selected or derived from structures 111-1 to HI-36 of Table 9 of W02018078053. Accordingly, formula 111-1 to HI-36 of WO2018078053, and the specific disclosure relating thereto, are herewith incorporated by reference. In embodiments, the at least one cationic lipid or ionizable lipid is selected or derived from formula HI-3 of WO2018078053. A preferred lipid of said formula III-3 has the chemical term ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), also referred to as ALC-0315, i.e. CAS Number 2036272-55-4.
[0299] Further suitable cationic or ionizable lipids may be selected or derived from lipids according to PCT claims 1-14 of WO2021123332, or Table 1 of WO2021123332, the disclosure relating thereto herewith incorporated by reference. Accordingly, suitable cationic or ionizable lipids may be selected or derived from lipids according to Compound 1 to Compound 27 (C1-C27) of Table 1 of WO2021123332.
[0300] In embodiments, the at least one cationic or ionizable lipid is selected or derived from SS-33 / 4PE-15 (see C23 in Table 1 of WO2021123332). In other embodiments, the at least one cationic or ionizable lipid is selected or derived from HEXA-C5DE-PipSS (see C2 in Table 1 of WO2021123332). In other embodiments, the at least one cationic or ionizable lipid is selected or derived from compound C26 (VitE-C4DE-Pip-thioether) as disclosed in Table 1 of WO2021123332.
[0301] In other embodiments, the at least one cationic or ionizable lipid is selected or derived from 9-Heptadecanyl 8-{(2- hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate, also referred to as SM-102.
[0302] Accordingly, in embodiments, the at least one cationic or ionizable lipid is selected or derived from C26, SM-102, SS- 33 / 4PE-15, HEXA-C5DE-PipSS, or ALC-0315.In embodiments, the lipid-based carrier, preferably the LNP, comprises at least one neutral lipid or phospholipid.
[0303] The term “neutral lipid” refers to any lipid species that exist in either an uncharged or neutral zwitterionic form at physiological pH. Neutral lipids may be selected from DHPC, DHPC, DOPC, DPPC, DOPG, DPPG, DOPE, POPO, POPE, DOPE-mal, DPPE, DMPE, DSPE, 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, SOPE, transDOPE, 1 ,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhyPE), DPhyPS (1 ,2-diphytanoyl-sn-glycero-3-phospho-L-serine), or mixtures thereof.
[0304] In embodiments, the at least one neutral lipid is selected or derived from DSPC, DHPC, DPhyPE, or DPhyPS. Preferred in that context is DSPC. In ether embodiments, the at least one neutral lipid is selected or derived from DPhyPE and / or DphyPS.
[0305] In embodiments, the lipid-based carrier, preferably the LNP, comprises a steroid, steroid analog, or sterol. In embodiments, the steroid, steroid analog or sterol is derived or selected from cholesterol, cholesteryl hemisuccinate (CHEMS), or any derivate of these. In preferred embodiments, the lipid-based carrier comprises cholesterol.
[0306] In preferred embodiments, the lipid-based carrier, preferably the LNP, comprising the artificial RNA, comprise
[0307] (i) at least one cationic lipid or ionizable lipid as defined herein;
[0308] (ii) at least one or two neutral lipids or phospholipids as defined herein;
[0309] (iii) at least one steroid or steroid analog as defined herein; and
[0310] (iv) at least one aggregation reducing lipid as defined herein.
[0311] In embodiments, the lipid-based carrier, preferably the LNP, comprise (i) to (iv) in a molar ratio of about 20-60% cationic lipid or ionizable lipid, about 5-25% neutral lipid, about 25-55% steroid or steroid analog, and about 0.5-15% aggregation reducing lipid e.g. polymer conjugated lipid.
[0312] The amount of lipid comprised in the lipid-based carrier such as LNP may be selected taking the amount of the nucleic acid cargo into account. These amounts are suitably selected such as to result in an N / P ratio of the lipid-based carrier comprising the nucleic acid (e.g. RNA) in the range of about 0.1 to about 50. The N / P ratio is defined as the mole ratio of the nitrogen atoms (“N”) of the basic nitrogen-containing groups of the lipid to the phosphate groups (“P”) of the nucleic add cargo. The N / P ratio may be calculated on the basis that, e.g., 1pg RNA typically contains about 3nmol phosphate residues, provided that the RNA exhibits a statistical distribution of bases. The “N”-value of the lipid may be calculated on the basis of its molecular weight and the relative content of permanently cationic and - if present - cationisable groups. In embodiments, the N / P ratio can be in the range of about 1 to about 50. In preferred embodiments, the range is from about 5 to about 20. In some embodiments, the N / P ratio is at about 17. In some embodiments, the N / P ratio is at about 14. In some embodiments, the N / P ratio is at about 6.
[0313] In various embodiments, the lipid-based carrier as defined herein such as the LNP as defined herein has a defined size (e.g. a defined particle size and / or a homogeneous size distribution).
[0314] The size of a lipid-based carrier such as an LNP is typically described as Z-average size. The term “Z-average size” refers to the mean diameter of particles as measured by dynamic light scattering (DLS) with data analysis using the so-called cumulant algorithm, which provides as results the so-called Z-average with the dimension of a length, and the polydispersity index (PDI), which is dimensionless. The term “dynamic light scattering” or “DLS” refers to a method for analyzing particles in a liquid, wherein the liquid is typically illuminated with a monochromatic light source and wherein the light scattered by particles in the liquid is detected. Suitable DLS protocols and instruments are known in the art. In embodiments, the lipid-based carrier, preferably the LNP, has a Z-average size of less than 400nm, preferably less than 300nm, more preferably less than 200nm. In preferred embodiments, the lipid-based carrier, preferably the LNP, has a Z-average size ranging from about 50nm to about 200nm, preferably about 50nm to about 150nm, more preferably about 50nm to about 120nm.
[0315] Guide RNA:
[0316] In embodiments, the composition comprises at least one guide RNA (gRNA) or a nucleic acid encoding the same, said gRNA being capable of targeting the CRISPR-associated endonuclease (that is provided by the at least one artificial RNA) to a target DNA sequence of interest, or a regulatory element operably linked thereto.
[0317] In this context, the composition may comprise (a) at least one artificial RNA encoding a CRISPR-associated endonuclease, and (b) at least one guide RNA (gRNA) or a nucleic acid encoding the same, said gRNA being capable of targeting the CRISPR-associated endonuclease to a target DNA sequence of interest, or a regulatory element operably linked thereto.
[0318] As used herein, the term “guide RNA” relates to any RNA molecule capable of targeting a CRISPR-associated endonuclease to a target DNA sequence of interest. Guide RNAs (gRNAs) preferably comprise a first region of complementarity that is capable of specifically hybridizing with a target DNA sequence and a second region that interacts with a CRISPR-associated protein. Said region, which is typically located at the 5' end of the gRNA, comprising a short nucleotide sequence that is complementary to a target DNA sequence, and is also referred to herein as a “targeting region”. The term “region” refers to a section / segment of a molecule, e.g., a contiguous stretch of nucleotides in an RNA. The targeting region may be about 17-20, e.g. about 21-23 nucleotides, in length or may longer or shorter (“truncated gRNA”). It may preferably interact with the target DNA sequence through hydrogen bonding between complementary base pairs (i.e., paired bases). The “gRNA” can be of any length, provided that it comprises a “targeting region” and is preferably capable of recruiting a CRISPR-associated endonuclease to a target DNA sequence in a sequence-specific manner. Therefore, “gRNAs” may be at least 10, 11 , 12 nucleotides in length, more preferably at least 13, 14, 15 nucleotides in length, and most preferably at least 16, 17, 18, 19, or 20 nucleotides in length. In some embodiments, the “gRNA” comprises a targeting region which is preferably at least 21 , 22, 23, 24, 25 nucleotides or more in length and ii) a second region that interacts with a CRISPR-associated protein. As used herein, the term “gRNA” includes two-molecule gRNAs as well as single-molecule RNAs.
[0319] The type II CRISPR-Cas9 system naturally employs two-molecule gRNAs. Such two-molecule gRNAs (“tracrRNA / crRNA”) typically comprises a crRNA (“CRISPR RNA” or “targeter-RNA” or “crRNA” or “crRNA repeat’) and a corresponding tracrRNA (“trans-acting CRISPR RNA” or “activator-RNA” or “tracrRNA”) molecule. A crRNA comprises both the targeting region (single stranded) and a stretch (“duplex-forming region”) of nucleotides that forms one half of the dsRNA duplex of the Cas9-binding region of the gRNA. A corresponding tracrRNA comprises a stretch ofnucleotides (duplex-forming region) that forms the other half of the dsRNA duplex of the Cas9-binding region of the gRNA. In other words, a stretch of nucleotides of a crRNA are complementary to and hybridize with a stretch of nucleotides of a tracrRNA to form the dsRNA duplex of the Cas9-binding region of the gRNA. As such, each crRNA can be said to have a corresponding tracrRNA. The crRNA additionally provides the single stranded targeting region. Thus, a crRNA and a tracrRNA (as a corresponding pair) hybridize to form a gRNA.
[0320] The crRNA and tracrRNA can also be joined to provide an (artificial) single-molecule guide RNAs (“single-guide RNAs”, “sgRNAs”). An “sgRNA” typically comprises a crRNA connected at its 3' end to the 5' end of a tracrRNA through a “loop” sequence. Similar to crRNA, sgRNA comprises a targeting region of complementarity to a target polynucleotide sequence, typically adjacent a second region that forms base-pair hydrogen bonds that form a secondary structure, typically a stem structure. “sgRNAs” are typically ~100 nucleotides in length, however, the term also includes truncated single-guide RNAs (tru-sgRNAs) of approximately 17-18 nt. The term also encompasses functional miniature sgRNAs with expendable features removed, which retain an essential and conserved module termed the “nexus” located in the portion of sgRNA that corresponds to tracrRNA (not crRNA). The nexus is located immediately downstream of (i.e. , located in the 3' direction from) the lower stem in Type II CRISPR-Cas9 systems. The term “sgRNA” also encompasses “deadRNAs” (“dRNAs”) comprising shortened targeting regions of 11-15 nucleotides. Such dRNAs can be used to recruit catalytically active Cas9 endonucleases to target DNA sequences for altering gene expression without inducing DSBs. sgRNA derivatives are also comprised by the term. Such derivatives typically include further moieties or entities conferring a new or additional functionality. Particularly, MS2 aptamers added to sgRNA tetraloop and / or stem-loop structures are capable of selectively recruiting effector proteins comprising said MS2 domains to the target DNA (“sgRNA-MS2”). Further modifications are also conceivable and envisaged herein.
[0321] The use of tracrRNA / crRNA or sgRNAs as gRNAs is not limited to Cas9 proteins. Any other CRISPR-associated system, preferably of the type II CRISPR-Cas system, may be used in connection with such gRNAs. However, other gRNAs may be required to ensure functionality of other CRISPR-Cas proteins, and such gRNAs are also encompassed in the respective definition. For instance, type V CRISPR-associated proteins, such as Cpf1 , is guided by a single and short (42-44 nt) crRNA as a gRNA, typically comprising single stem loop in a direct repeat sequence.
[0322] In embodiments, (a) the at least one artificial RNA encoding the at least one CRISPR-associated endonuclease, and (b) the at least one guide RNA (gRNA), are co-formulated in one or more cationic or polycationic compound as defined herein, preferably in a lipid-based carrier as defined herein, most preferably in an LNP as defined in section “lipid-based carriers”. Accordingly, in embodiments in this context, the pharmaceutical composition comprises at least one lipid-based carrier, preferably at least one LNP that comprises the at least one artificial RNA encoding the at least one CRISPR-associated endonuclease and the at least one gRNA.
[0323] In alternative embodiments, (a) the at least one artificial RNA encoding the at least one CRISPR-associated endonuclease, and (b) the at least one guide RNA (gRNA), are formulated separately in one or more cationic or polycationic compound as defined herein, preferably in a lipid-based carrier as defined herein, most preferably in an LNP as defined in section “lipid-based carriers”. Accordingly, in embodiments in this context, the pharmaceutical composition comprises at least two lipid-based carriers, preferably at least two LNPs, wherein one lipid-based carrier comprises theat least one artificial RNA encoding the at least one CRISPR-associated endonuclease and one lipid-based carrier comprises the at least one gRNA
[0324] 3: A kit or kit of parts:
[0325] In a third aspect, the invention provides a kit or kit of parts comprising at least one artificial RNA of the first aspect and / or at least one composition of the second aspect.
[0326] It should be noted that features and embodiments described in the context of the first aspect (the artificial RNA), or the second aspect (composition), must be read on and must be understood as suitable embodiments of the kit or kit of parts of the third aspect.
[0327] In embodiments, the kit or kit of parts, comprises (i) the artificial RNA as defined in the first aspect and / or (ii) the pharmaceutical composition as defined in the second aspect, and, optionally, a liquid vehicle and / or technical instructions with information on the administration and dosage of the artificial RNA or the pharmaceutical composition. In embodiments, the kit or kit of parts comprises the following components, preferably in different containers / vials: component A: at least one artificial RNA encoding a CRISPR-associated endonuclease, or a pharmaceutical composition comprising at least one artificial RNA encoding a CRISPR-associated endonuclease; and component B: at least one guide RNA (gRNA) or a nucleic acid encoding the same, said gRNA being capable of targeting the CRISPR-associated protein to a target DNA sequence of interest, or a regulatory element operably linked thereto.
[0328] 4: Medical uses:
[0329] In a fourth aspect, the invention relates to the medical use of the subject matter of any of the foregoing aspects.
[0330] It should be noted that features and embodiments described in the context of the first aspect (the artificial RNA) or the second aspect (the composition) or the third aspect (kit or kit of parts) must be read on and must be understood as suitable embodiments of the present aspects (medical uses) and vice versa.
[0331] Accordingly, the invention provides the artificial RNA of the first aspect, the pharmaceutical composition of the second aspect, or the kit or kit of parts of the third aspect, for use as a medicament.
[0332] Preventing (inhibiting) or treating a disease relates to inhibiting the full development of a disease or condition, for example, in a subject who is at risk for a disease such as an infection or cancer. “Treatment" refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop. The term “ameliorating”, with reference to a disease or pathological condition, refers to any observable beneficial effect of the treatment. Inhibiting a disease can include preventing or reducing the risk of the disease. The beneficial effect can be evidenced, for example, by a delayed onset of clinical symptoms of the disease in a susceptible subject, a reduction in severity of some or all clinical symptoms of the disease, a slower progression of the disease, an improvement in the overall health or well-being of the subject, or by other parameters that are specific to the particular disease. A “prophylactic” treatment is a treatment administered to a subject who does not exhibit signs of a disease or exhibits only early signs for the purpose of decreasing the risk of developing pathology.In preferred embodiments, the use may be for human medical purposes and for veterinary medical purposes, preferably for human medical purposes. In preferred embodiments, the use may be for human medical purposes, in particular, for young infants, newborns, immunocompromised recipients, pregnant and breast-feeding women, and elderly people. Accordingly, the invention provides the artificial RNA of the first aspect, the pharmaceutical composition of the second aspect, or the kit or kit of parts of the third aspect, for use in gene therapy.
[0333] In this context, it is preferred that the artificial RNA of the first aspect, the pharmaceutical composition of the second aspect, or the kit or kit of parts of the third aspect provide an artificial RNA that encodes at least one CRISPR-associated endonuclease and, optionally, at least one gRNA.
[0334] In embodiments, the provided artificial RNA that encodes at least one CRISPR-associated endonuclease comprises or consists of a nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 608-610, 619-654, 662-667, or a fragment or variant of any of these sequences. In preferred embodiments, the provided artificial RNA that encodes at least one CRISPR-associated endonuclease comprises or consists of an N1 -methylpseudouridine modified nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 609, 631-642, 662-667. In alternative embodiments, the provided artificial RNA that encodes at least one CRISPR-associated endonuclease comprises or consists of a pseudouridine modified nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 610, 643-654. In more preferred embodiments, the provided artificial RNA that encodes at least one CRISPR-associated endonuclease comprises or consists of an N1 -methylpseudouridine modified nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 609. In even more preferred embodiments, the provided artificial RNA that encodes at least one CRISPR-associated endonuclease comprises or consists of an N1 -methylpseudouridine modified nucleic acid sequence identical to SEQ ID NOs: 609. In particularly preferred embodiments, the provided artificial RNA that encodes at least one CRISPR-associated endonuclease consists of an N1-methylpseudouridine modified nucleic acid sequence identical to SEQ ID NOs: 609, and wherein the artificial RNA comprises a 5’ cap1 structure.
[0335] “Gene therapy” preferably involves modulating (i.e. restoring, enhancing, decreasing or inhibiting) gene expression in a subject in order to achieve a therapeutic effect. To this end, gene therapy typically encompasses the introduction of nucleic acids into cells. The term generally refers to the manipulation of a genome for therapeutic purposes and includes the use of genome-editing technologies for correction of mutations that cause disease, the addition of therapeutic genes to the genome, the removal of deleterious genes or genome sequences, and the modulation of gene expression. Gene therapy may involve in vivo or ex vivo transformation of the host cells.
[0336] The invention also provides the artificial RNA of the first aspect, the pharmaceutical composition of the second aspect, or the kit or kit of parts of the third aspect, for use in a method of modulating the expression of a gene of interest, comprising administering to a patient in need thereof (a) said artificial RNA, said pharmaceutical composition or said kit and (b) a guide RNA (gRNA) or a nucleic acid encoding the same, said sgRNA being capable of targeting the CRISPR- associated protein to a gene of interest, or a regulatory element operably linked thereto.The invention also provides the artificial RNA of the first aspect, the pharmaceutical composition of the second aspect, or the kit or kit of parts of the third aspect, for use as a medicament or for use in gene therapy in a disease, disorder or condition amenable by knocking in, knocking out or manipulating a gene of interest, or by modulating the expression of a gene of interest
[0337] Accordingly, the present invention further provides methods of treating diseases amenable to treatment by expression of the encoded CRISPR-associated protein, preferably amenable to treatment by knocking in, knocking out, manipulating or modulating the expression of a gene of interest, by administering to a subject in need thereof a pharmaceutically effective amount of the artificial RNA, or the (pharmaceutical) composition or kit-of-parts. Such methods may comprise an optional first step of preparing the inventive RNA molecule, or the (pharmaceutical) composition or kit-of-parts, and a second step, comprising administering (a pharmaceutically and / or therapeutically effective amount of) said artificial RNA, or the (pharmaceutical) composition or kit-of-parts to a patient / subject in need thereof.
[0338] Administration is preferably accomplished parenterally, for instance by subcutaneous, intramuscular or intradermal injection, preferably by intramuscular or intradermal injection. Preferably, injection is carried out by using conventional needle injection or (needle-free) jet injection.
[0339] The invention also relates to the use of the inventive artificial RNA, or the (pharmaceutical) composition or kit-of-parts, preferably for knocking-in, knocking-out, manipulating or modulating, preferably for inducing or enhancing, expression of a gene of interest.
[0340] In the context of any medical use disclosed herein, the disease, disorder or condition is selected from genetic diseases, cancer, autoimmune diseases, inflammatory diseases, and infectious diseases.
[0341] 5: Methods of treatment:
[0342] In a fifth aspect, the present invention relates to a method of treating or preventing a disease, disorder or condition. It should be noted that features and embodiments described in the context of the first aspect (the artificial RNA) or the second aspect (composition) or the third aspect (kit or kit of parts) or the fourth aspect aspects (medical uses) must be read on and must be understood as suitable embodiments of the present aspects (methods of treatment).
[0343] In embodiments, the present invention relates to a method of treating or preventing a disease, disorder or condition, wherein the method comprises applying or administering to a subject in need thereof an effective amount of an artificial RNA of the first aspect, a composition of the second aspect, a kit or kit of parts of the third aspect.
[0344] In preferred embodiments, the method of treating or preventing a disease, disorder, or condition is further characterized by any one of the features as disclosed in the fourth aspect (“medical use”).
[0345] 6: Use of a minimized Gnas 3’ UTR for improving the translation efficiency of an RNA
[0346] In a sixth aspect, the present invention provides the use of a minimized Gnas 3’ UTR for improving the translation efficiency of an RNA, preferably a modified RNAIt should be noted that features and embodiments described in the context of the first aspect (the artificial RNA) or the second aspect (composition) or the third aspect (kit or kit of parts) or the fourth aspect (medical uses) must be read on and must be understood as suitable embodiments of the present aspects (use of a minimized Gnas).
[0347] A minimized Gnas 3’UTR sequence (Gnas-min) as defined herein displays, when incorporated into an RNA molecule, several unexpected advantageous properties. Surprisingly, the expression efficiency of an RNA construct comprising a minimized Gnas 3’UTR is increased compared with a reference RNA construct comprising the full length Gnas 3’UTR. Accordingly, the invention provides the use of a minimized Gnas 3' UTR (Gnas-min) for improving the translation efficiency of an RNA.
[0348] Preferably, an RNA that comprises a minimized Gnas 3’ UTR (Gnas-min) is characterized by advantageous properties when it comes to the incorporation of modified nucleotides (see also section “modified nucleotides”). As unexpectedly observed by the inventors, minimizing a 3’ Gnas UTR as defied herein, in other words reducing the length of the full length Gnas 3’ UTR from e.g. 353 nucleotides to a smaller size, preferably to 70 to 150 nucleotides, allowed for a modification of this minimized Gnas UTR with e.g. modified nucleotides without causing a translational loss / a reduction in translation efficiency. Translation efficiency is very often negatively affected by chemical modification of the 3’ UTR because it is believed that protein interaction is reduced by chemical modifications. As the 3’ UTR region has a paramount importance for regulating the in vivo translation of an RNA into a protein, hampering protein interactions with e.g. factors that impact RNA stability and / or translation is obviously not desired. As Gnas-min comprises A / U rich sequence elements, it was a surprising and unexpected finding that Gnas-min can be modified (e.g. by using modified uridine nucleotide such as, e.g., pseudouridine (yr) or N1 -methylpseudouridine (ml i )) essentially without causing a translational loss I a reduction in translation efficiency.
[0349] In embodiments, Gnas-min is integrated into an RNA, in particular an artificial RNA as defined in the first aspect, preferably a modified artificial RNA as defined in the first aspect. Gnas-min may be integrated into an RNA, preferably a modified RNA that comprises at least one cds as defined herein, encoding at least one therapeutic peptide or protein as defined herein. Gnas-min is integrated into an RNA that may comprise further elements such as a 5' UTR as defined herein, a 5’ Cap structure as defined herein, a Poly(N) sequence as defined herein, a hsl as defined herein, etc.
[0350] Preferably, Gnas-min consists of a section of 70 to 140 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0351] In embodiments of the use, Gnas-min is further characterized by any one of the features of the section “minimized Gnas 3’ UTR sequence element” of the first aspect.
[0352] In embodiments of the use, Gnas-min consists of a section of, with increasing preference, 80 to 150, 90 to 140, 100 to 130, 110 to 120, consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).In preferred embodiments of the use, Gnas-min consists of a section of 110 to 120 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0353] In embodiments of the use, Gnas-min consists of a section of 70, 71, 72, 63, 74, 75, 86, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0354] In preferred embodiments of the use, the respective section contained in Gnas-min is taken from the 3’ terminal end of the nucleic acid sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0355] In embodiments of the use, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 5-7, 53-607, ora modified version of any of these, preferably an N1 -methylpseudouridine (mlqj)-modified sequence version of any of these. In embodiments of the use, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 5-7, 53-131. In embodiments of the use, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 82-91,213-607. In preferred embodiments of the use, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 82-91. In more preferred embodiments of the use, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to identical to SEQ ID NOs: 1-3. In particularly preferred embodiments of the use, Gnas-min consists of a nucleotide sequence identical to SEQ ID NO: 2.
[0356] In preferred embodiments of the use, Gnas-min comprises at least one modified nucleotide preferably at least one modified nucleotide as defined in section “modified nucleotides” of the first aspect In preferred embodiments, the at least one modified nucleotide is selected from pseudouridine or N1 -methylpseudouridine.
[0357] In particularly preferred embodiments of the use, 100% of the uracil in the nucleic acid sequence of Gnas-min are substituted with pseudouridine or N1 -methylpseudouridine, preferably with N1 -methylpseudouridine.
[0358] In preferred embodiments in this context, Gnas-min is integrated into a modified RNA, preferably wherein the modified RNA comprises at least one modified nucleotide as defined in section “modified nucleotides” of the first aspect. In preferred embodiments, the modified RNA comprises a modified nucleotide selected from pseudouridine or N1- methylpseudouridine.
[0359] Suitably, Gnas-min is integrated into a modified RNA, preferably a modified mRNA, wherein 100% of the uracil in the RNA sequence are substituted with pseudouridine or N1 -methylpseudouridine, preferably with N1 -methylpseudouridine.In particular, the combination of a HSD17B45’ UTR sequence and a Gnas-min 3’-UTR sequence allows for the use of modified nucleotides (e.g. modified uridine nucleotide such as, e.g., pseudouridine (i ) or N1 -methylpseudouridine (ml i )) without a translational loss / a reduction in translation efficiency.
[0360] Accordingly, in embodiments of the use, the RNA (comprising Gnas-min) comprises at least one 5’ UTR sequence element from HSD17B4 comprising or consisting of a nucleic acid sequence being identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 24-26, or a fragment or variant thereof, preferably SEQ ID NOs: 25, or a fragment or variant thereof.
[0361] Accordingly, in embodiments of the use, when administered to a cell or subject, the translation efficiency of an RNA (comprising Gnas-min) is improved compared to the translation efficiency of a reference RNA that comprises a full length Gnas 3’ UTR sequence .In preferred embodiments of the use, when administered to a cell or subject, the translation efficiency of an RNA (comprising Gnas-min) that contains at least one modified nucleotide, preferably N1-methylpseudouridine, is improved compared to the translation efficiency of a reference RNA that comprises a full length Gnas 3’ UTR sequence and that contains at least one modified nucleotide, preferably N1 -methylpseudouridine.
[0362] A “reference RNA” in this context is essentially identical to the RNA of the use, with the exception that the reference RNA comprises the full length Gnas 3’ UTR instead of Gnas-min. Accordingly, for sake of comparability, the "reference RNA” in this context comprises, if present, an identical cds, an identical Cap structure, an identical poly(A), an identical 5’ UTR, an identical hsl, an identical modification pattern - however, as defined above, the reference RNA comprises the full length Gnas 3’ UTR (SEQ ID NO: 8), whereas the RNA of the use comprises Gnas-min as defined herein.
[0363] In embodiments, the translation efficiency of an RNA that comprises Gnas-min that contains at least one modified nucleotide, preferably N1 -methylpseudouridine (e.g. an RNA comprising SEQ ID NO: 2), is essentially equal compared with the translation efficiency of an RNA of the use that comprises Gnas-min and does not contain at least one modified nucleotide (e.g. an artificial RNA comprising SEQ ID NO: 1).
[0364] In embodiments of the use, the translation efficiency of a modified RNA that contain Gnas-min is improved, in particular increased by at least 1%, 2%, 5%, 10%, 20%, 25% or more, compared to the respective reference RNA. The translation efficiency may be determined by detecting the encoded peptide or protein in a cell upon administration of a modified RNA comprising Gnas-min compared to the respective reference RNA
[0365] In embodiments of the use, immune stimulation caused by a modified RNA that contain Gnas-min, in particular the induction of INFa, is reduced compared to a modified reference RNA comprises the full length Gnas 3’ UTR.
[0366] 7: Use of a minimized Gnas UTR for improving the manufacturability of an RNA
[0367] In a seventh aspect, the present invention provides the use of a minimized Gnas 3’ UTR for improving the manufacturability of an RNA. It should be noted that features and embodiments described in the context of the first aspect (the artificial RNA) or the second aspect (composition) or the third aspect (kit or kit of parts) or the fourth aspect aspects (medical uses) must be read on and must be understood as suitable embodiments of the present aspects (use of a minimized Gnas).Preferably, an RNA that comprises Gnas-min is characterized by some advantageous properties when it comes to the manufacturability of the artificial RNA. Typically, an RNA is produced in a process called “RNA in vitro transcription”. This in vitro synthesis process typically generates unwanted by-products such as abortive RNA sequences, double stranded RNA sequences, or other by-products. However, it is of desired especially in the context of large-scale manufacturing of an RNA when e.g. used as a medicament, that the production process produces only small amounts of by-products and produces large quantities of intact, full-length RNA. As unexpectedly observed by the inventors, minimizing the 3’ Gnas UTR as defied herein, in other words reducing the length of the full length Gnas 3’ UTR from e.g. 353 nucleotides to a smaller size, preferably to 70 to 150 nucleotides, reduced the impurity profile of the artificial RNA after RNA in vitro transcription. This is especially important in the context of producing larger RNA species (e.g. RNA encoding larger proteins such as CRISPR-associated endonucleases), as larger RNA species are typically more challenging when it comes to manufacturability.
[0368] In embodiments of the use, the RNA (to be manufactured) comprises at least one coding sequence as defined herein, encoding at least one therapeutic peptide or protein as defined herein. Gnas-min is used to improve the manufacturability of an RNA that may comprise further elements such as a 5’ UTR as defined herein, a 5’ Cap structure as defined herein, a Poly(N) sequence as defined herein, a hsl as defined herein, etc. In preferred embodiments of the use, the RNA is an mRNA.
[0369] In embodiments of the use for improving the manufacturability of an RNA, Gnas-min consists of a section of 70 to 140 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0370] In embodiments of the use, Gnas-min is further characterized by any one of the features of the section “minimized Gnas 3’ UTR sequence element’ of the first aspect.
[0371] In embodiments of the use, Gnas-min consists of a section of, with increasing preference, 80 to 150, 90 to 140, 100 to 130, 110 to 120, consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0372] In preferred embodiments of the use, Gnas-min consists of a section of 110 to 120 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0373] In embodiments of the use, Gnas-min consists of a section of 70, 71, 72, 63, 74, 75, 86, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).In preferred embodiments of the use, the respective section contained in Gnas-min is taken from the 3’ terminal end of the nucleic add sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, or a chemically modified nucleic acid sequence thereof (SEQ ID NO: 6 or 7).
[0374] In embodiments of the use, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1 -3, 5-7, 53-607, or a modified version of any of these, preferably an N1 -methylpseudouridine (mlqj)-modified sequence version of any of these. In embodiments of the use, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 5-7, 53-131. In embodiments of the use, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 82-91, 213-607. In preferred embodiments of the use, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 82-91. In more preferred embodiments of the use, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to identical to SEQ ID NOs: 1-3. In particularly preferred embodiments of the use, Gnas-min consists of a nucleotide sequence identical to SEQ ID NO: 2.
[0375] The advantage of manufacturability is mostly pronounced in embodiments where the artificial RNA comprises 3500 to 10000 nucleotides, 3500 to 7500 nucleotides, preferably 3500 to 5000 nucleotides.
[0376] In embodiments of the use, the encoded therapeutic peptide or protein is encoded by a coding sequence that has a length of at least 3500 nucleotides, 4000 nucleotides, 4500 nucleotides.
[0377] Furthermore, advantageously, the manufacturability of an RNA that comprises a combination of a HSD17B45' UTR sequence and a Gnas-min 3’-UTR sequence can be improved, even in embodiments where the RNA comprises large coding sequences which leads to very long RNA sequences (e.g. in embodiments where the artificial RNA also comprises a 5’ UTR sequence element as defined herein and a 3’ Poly(A) and / or a histone-stem loop).
[0378] In embodiments of the use, the RNA comprises at least one 5’ untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element from HSD17B4 comprising or consisting of a nucleic acid sequence being identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 24-26, or a fragment or variant thereof, preferably SEQ ID NOs: 25, or a fragment or variant thereof.
[0379] Accordingly, in preferred embodiments of the use, the content of impurities contained in a preparation of RNA that contains Gnas-min is reduced during or after manufacturing compared to the content of impurities contained in a preparation of a reference RNA that comprises a fell length Gnas 3’ UTR sequence.
[0380] In embodiments of the use, the RNA integrity of an RNA that contains Gnas-min is increased during or after manufacturing compared to the RNA integrity of a reference RNA that comprises a fell length Gnas 3’ UTR sequence. RNA integrity can be determined by RP-HPLC and may be based on determining the area under the peak of the expected fell-length RNA in a chromatogram.In embodiments of the use, the dsRNA content of an RNA that contains Gnas-min is decreased during or after manufacturing compared to the dsRNA content of a reference RNA that comprises a full length Gnas 3’ UTR sequence. dsRNA content can be determined by dsRNA Elisa using dsRNA-specific antibodies.
[0381] During manufacturing typically means during the process of RNA in vitro transcription before subjecting the produced RNA preparation to purification steps. After manufacturing typically means after the process of RNA in vitro transcription and after subjecting the produced RNA preparation to purification steps.
[0382] A “reference RNA” in this context is essentially identical to the RNA (that contains Gnas-min), with the exception that the reference RNA comprises the full length Gnas 3’ UTR (SEQ ID NO: 8), instead of Gnas-min. Accordingly, for sake of comparability, the “reference RNA” in this context comprises, if present, an identical cds, an identical Cap structure, an identical poly(A), an identical 5’ UTR, an identical hsl, an identical modification pattern - however, as defined above, the reference RNA comprises the full length Gnas 3’ UTR whereas the RNA of the use comprises Gnas-min.
[0383] 8: A method for producing an artificial RNA:
[0384] In an eighth aspect, the present invention provides a method for producing an artificial RNA.
[0385] It should be noted that features and embodiments described in the context of the first aspect (the artificial RNA) or the second aspect (composition) or the third aspect (kit or kit of parts) or the fourth aspect aspects (medical uses) or the sixth and seventh aspect must be read on and must be understood as suitable embodiments of the present aspects (method for producing the artificial RNA).
[0386] In embodiments, the method for producing an artificial RNA comprising at least one coding sequence comprises the following steps
[0387] (A) providing a DNA template comprising at least on coding sequence and at least one 3’ UTR comprising at least one Gnas-min, wherein Gnas-min consists of a section of 70 to 140 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, wherein Gnas-min is preferably further characterized by any one of the features disclosed in section “Minimized Gnas 3’ UTR sequence element” of the first aspect; (B) obtaining a preparation comprising the artificial RNA by at least one step of RNA in vitro transcription;
[0388] (C) purifying the obtained preparation by at least one step of purification;
[0389] (D) formulating the purified artificial RNA in a lipid-based carrier by at least one step of formulation.
[0390] In preferred embodiments of the method, the artificial RNA to be manufactured is an artificial as defined in the context of the first aspect. Accordingly, the artificial RNA to be manufactured may comprise a Cap as defined in the first aspect, a 5’ UTR as defined in the first aspect, a coding sequence as defined in the first aspect, a modification as defined in the first aspect, a Poly(N) sequence as defined in the first aspect, a hsl as defined in the first aspect.
[0391] In preferred embodiments of the method, the coding sequence is as defined herein, preferably encoding a CRISPR- associated endonuclease as defined in section “Coding sequences encoding CRISPR-associated endonucleases” of the first aspect.In embodiments of the method, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 5-7, 53-607, or a modified version of any of these, preferably an N1-methylpseudouridine (mlqj)-modified sequence version of any of these. In embodiments of the method, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 5-7, 53-131. In embodiments of the method, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 82-91, 213-607. In preferred embodiments of the method, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3,82-91. In more preferred embodiments of the method, Gnas-min comprises or consists of a nucleotide sequence that is identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to identical to SEQ ID NOs: 1-3. In particularly preferred embodiments of the method, Gnas-min consists of a nucleotide sequence identical to SEQ ID NO: 2.
[0392] In embodiments, the artificial RNA comprises 3500 to 10000, 3500 to 7500, preferably 3500 to 5000 nucleotides. In preferred embodiments of the method, the 5’ untranslated region (5’ UTR) comprises at least one 5' UTR sequence element from HSD17B4 comprising or consisting of a nucleic acid sequence being identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 24-26, or a fragment or variant thereof, preferably SEQ ID NOs: 25, or a fragment or variant thereof.
[0393] In embodiments of the method, the artificial RNA to be manufactured comprises or consists of a nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 608-610, 619-654, 662-667, or a fragment or variant of any of these sequences. In preferred embodiments of the method, the artificial RNA to be manufactured comprises or consists of an N1-methylpseudouridine modified nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 609, 631-642, 662- 667, or a fragment or variant of any of these sequences.
[0394] In particularly preferred embodiments of the method, the artificial RNA to be manufactured comprises or consists of an N1 -methylpseudouridine nucleic acid sequence which is identical to, or at feast 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 609.
[0395] Preferably, the RNA is obtained by transcribing a DNA template in the presence of a DNA-dependent RNA polymerase (e.g. T7, SP6), ribonucleotide triphosphates (NTPs, and optionally modified NTPs) and optionally, a cap analog, in an appropriate buffer (e.g. comprising MgCI2). Advantageously, an RNA in vitro transcription to generate the artificial RNA of the invention comprising Gnas-min produces less by-products and impurities compared to an RNA in vitro transcription to generate a reference RNA that comprises a full-length Gnas 3’ UTR element.
[0396] In preferred embodiments, the method yields a purified mRNA. The term “purified RNA” refers to RNA which has a higher purity after certain purification steps than the starting material. Typical impurities comprise peptides, proteins, spermidine, RNA fragments, dsRNA, free nucleotides, DNA, etc. It is desirable for the “degree of RNA purity" to be asclose as possible to 100%. Preferably, a “purified RNA” has a degree of purity of more than 75%, 80%, 85%, 90%, or 95%. The degree of purity may be determined by an analytical HPLC.
[0397] In embodiments of the method, step D comprises a step of (RP)HPLC, AEX, size exclusion chromatography (SEC), hydroxyapatite chromatography, tangential flow filtration (TFF), filtration, precipitation, core-bead flowthrough chromatography, oligo(dT) purification, and / or cellulose-based purification. Preferably, step D comprises (RP)HPLC (suitably as described in W02008077592), TFF (suitably as described in WO2016193206), and / or oligo d(T) purification. More preferably, step D comprises at least one step of TFF.
[0398] In embodiments of the method, the obtained artificial RNA has an integrity of at least 60%, 70%, 80%, 90%. The term “RNA integrity” describes whether the complete RNA sequence is present. In preferred embodiments, the artificial RNA has an integrity that is at least 5%, 10%, 15% higher than the integrity value of a reference RNA that comprises a full-length Gnas 3’ UTR element. RNA integrity can be determined by RP-HPLC and may be based on determining the area under the peak of the expected full-length RNA in a chromatogram.
[0399] In embodiments, the dsRNA content contained in the obtained preparation of the artificial RNA (comprising Gnas-min) is decreased during or after manufacturing compared to the dsRNA content contained in a preparation of a reference RNA that comprises a full length Gnas 3’ UTR sequence. The dsRNA content can be determined by dsRNA Elisa using dsRNA-spedfic antibodies.
[0400] In embodiments of the method, step E comprises formulating the purified artificial RNA in a lipid-based carrier, wherein the lipid-based carrier is an LNP.
[0401] Brief description of the figures:
[0402] Figure 1 shows in vitro expression after 6, 24, and 72 hours in HeLa cells of RNA constructs that comprise different 3’UTR Gnas sequence elements (see Table 1) compared to RNA constructs comprising the full length 3'UTR Gnas(1-353) sequence. Further details provided in Example 1.3.
[0403] Figure 2A shows an HPLC chromatogram of RNA constructs comprising the full length 3’UTR Gnas(1-353)
[0404] sequence. Arrow indicates an unwanted impurity. Further details provided in Example 3.3.
[0405] Figure 2B shows an HPLC chromatogram of RNA constructs comprising the full length 3’UTR Gnas(1-353) sequence after oligo(dT) purification. Further details provided in Example 3.3.
[0406] Figure 3 shows the Cas9 / actin ratio of in vitro expressed modified RNA constructs comprising a minimized 3'UTR Gnas(240-353) sequence element (Gnas-min). Further details are shown in Example 3.4. Figure 4 shows INFa levels in PBMCs after transfection with high (white bars) or low (black bars) doses of unmodified and modified RNA comprising a minimized 3’UTR Gnas(240-353) sequence (Gnas-min) or comprising the full length 3'UTR Gnas(1-353) sequence. Further details provided in Example 3.5. Figure 5A shows the amount of produced Cas9 protein for different RNA doses of RNA constructs comprising a minimized 3’UTR Gnas(240-353) sequence element (Gnas-min) and different poly(A) sequence lengths (25, 60, 80, 100, 120 and 140 adenosines). Further details provided in Example 3.6.
[0407] Figure 5B shows the amount of produced Cas9 protein for different RNA doses of RNA constructs comprising a minimized 3’UTR Gnas(240-353) and different poly(A) sequence lengths (80, 100 and 120 adenosines). Further details provided in Example 3.6.Examples:
[0408] In the following, examples illustrating various embodiments and aspects of the invention are presented. However, the present invention shall not to be limited in scope by the specific embodiments presented herein and should rather be understood as being applicable to other compositions or uses as for example defined in the specification. Accordingly, the following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. Indeed, various modifications of the invention in addition to those described herein will become readily apparent to those skilled in the art from the foregoing description, accompanying figures and the examples below.
[0409] Example 1 : In vitro expression of RNA with a minimized Gnas 3’ UTR sequence element (Gnas-min) The goal of the experiment was to compare the expression of RNA constructs comprising a minimized 3’UTR Gnas(240-353) sequence element (Gnas-min) with RNA constructs comprising other sequence fragments of the Gnas 3’UTR and an RNA construct comprising the full length 3’UTR of Gnas(1-353). Upon administration of these RNA constructs, Gaussia luciferase (GpLuc) levels were measured in HeLa cell lines 6, 24 and 72 hours post transfection.
[0410] 1.1 : Preparation of DNA templates for RNA in vitro transcription
[0411] DNA sequences encoding GpLuc were prepared and used for subsequent RNA in vitro transcription reactions. DNA sequences were prepared by modifying the wild type or reference encoding DNA sequences by introducing a G / C optimized coding sequence for stabilization and expression optimization. Sequences inter alia contained a T7 promoter sequence, a 5’UTR, a coding sequence encoding GpLuc, a 3’ UTR comprising the respective Gnas 3’UTR element, and a Poly(A) sequence. Features of the used RNA constructs are provided in Table 1.
[0412] Table 1: RNA constructs used in Example 1
[0413]
[0414] 1.2: Preparation of DNA templates for RNA in vitro transcription
[0415] DNA templates were used for DNA dependent RNA in vitro transcription (IVT) using T7 RNA polymerase in the presence of a sequence optimized nucleotide mixture (ATP / GTP / CTP / UTP) and cap analog (forcapO: m7G(5’)ppp(5’)pG) under suitable buffer conditions. After RNA in vitro transcription, the obtained RNA IVT reaction was subjected to purification steps comprising RP-HPLC.
[0416] 1.3: In vitro expression in HeLa cells
[0417] HeLa cells were seeded 24 hours before transfection on 96 well plates (10,000 cells in 200pl / well) in a compatible complete cell medium. Cells were maintained at 37°C, 5% CO2. The day of transfection, the complete medium was replaced with serum-free Opti-MEM medium (Thermo Fisher). Each RNA was complexed with Lipofectamine 2000 at a ratio of 1 / 1.5 (w / v) for 20 minutes in Opti-MEM. Lipocomplexed RNA conjugates and control RNA were then added to cells for transfection with 50ng per well in a total volume of 200pl.On hour 6, 24 and 72 post start of transfection, GpLuc expression was measured in cell supernatants. Supernatants were harvested at each time point of collection and stored at -80°C.200pl of fresh cell culture medium were added to the cells. For measurement, 10pl were transferred into white LIA assay plates (Greiner Cat.655075). Plates were introduced into a Berthold T ristar plate reader with injection device for Renillajuice containing substrate for Gaussia luciferase. Per well, 50pl of Renillajuice were added and GpLuc luminescence was measured by Berthold Tristar plate reader. After transfection of RNA constructs (listed in Table 1 ) in HeLa cells, substantially increased expression levels were detected for the RNA construct comprising a minimized 3’UTR Gnas(240-353) sequence element compared to the RNA constructs comprising other Gnas fragments or the full length Gnas 3’UTR (see Figure 1 ). This effect was particularly pronounced when considering long-term expression (72h post transfection) where the RNA construct comprising a minimized 3’UTR Gnas(240-353) sequence element showed strongly increased expression levels.
[0418] Example 2: In vitro expression of modified and unmodified RNA comprising a Gnas-min
[0419] The goal of this experiment was to investigate the influence of modified nucleotides on the expression of RNA constructs comprising a minimized 3’UTR Gnas(240-353) sequence element (Gnas-min). HepG2 cells were transfected with modified and unmodified RNA constructs comprising a minimized 3’UTR Gnas(240-353) sequence element or corresponding reference RNA constructs comprising the full length 3’UTR Gnas(1-353) sequence.
[0420] 2.1. Preparation of DNA templates for RNA in vitro transcription
[0421] DNA sequences encoding PpLuc were prepared and used for subsequent RNA in vitro transcription reactions. DNA sequences were prepared by modifying the wild type or reference encoding DNA sequences by introducing a G / C optimized coding sequence for stabilization and expression optimization. Sequences were introduced into a pUC derived DNA vector to comprise the 5’UTR HSD17B4 and a minimized 3’UTR Gnas(240-353) sequence element or the full length 3’UTR Gnas(1 -353) and a Poly(A) sequence. The obtained plasmid DNA templates were transformed and propagated in bacteria using common protocols known in the art. Eventually, the plasmid DNA templates were extracted, purified, and linearized. The herein used RNA constructs are provided in Table 2.
[0422] Table 2: RNA constructs used in example 2
[0423]
[0424] 2.2. RNA in vitro transcription from plasmid DNA templates
[0425] Linearized DNA templates were used for DNA dependent RNA in vitro transcription (IVT) using T7 RNA polymerase in the presence of a sequence optimized nucleotide mixture (ATP / GTP / CTP / UTP) and cap analog (for cap1 : m7G(5’)ppp(5’)(2’OMeA)pG; TriLink) under suitable buffer conditions. Other constructs were produced in the presence of a nucleotide mixture comprising (ATP / GTP / CTP / Pseudo-UTP (i )) and a cap analog. After RNA in vitro transcription, the obtained RNA IVT reaction was subjected to purification steps comprising RP-HPLC and / or TFF.2.3. In vitro expression of modified and unmodified RNA comprising a Gnas-min
[0426] HepG2 cells were seeded 24 hours before transfection on 96 well plates (10,000 cells in 200pVwell) in a compatible complete cell medium. Cells were maintained at 37°C, 5% CO2. The day of transfection, the complete medium was replaced with serum-free Opti-MEM medium (Thermo Fisher). Each RNA was complexed with Lipofectamine 2000 at a ratio of 1 / 1.5 (w / v) for 20 minutes in Opti-MEM. Lipocomplexed RNA conjugates and control RNA were then added to cells for transfection with 50ng per well in a total volume of 200pl.
[0427] On hour 24 post start of transfection, PpLuc expression was measured in cell lysates. Cells were harvested at each time point of collection and lysis buffer was added and cell lysates were stored at -80°C. For measurement, 20 I were transferred into white LIA assay plates (Greiner Cat.655075). Plates were introduced into a Berthold Tristar plate reader with injection device for Beetle-juice containing substrate for firefly luciferase. Per well, 50pl of beetle-juice were added and PpLuc lumincescence was measured by Berthold Tristar plate reader.
[0428] After measurement of the expression of the RNA constructs, results were normalized to the respective reference RNA construct comprising the full length 3’UTR Gnas(1-353) sequence (Table 3). Surprisingly, strongly increased expression levels were detected for RNA constructs comprising a minimized 3’UTR Gnas(240-353) sequence element This effect was highly pronounced for Pseudo-UTP-modified RNA constructs where the detected expression for RNA constructs comprising a minimized 3’UTR Gnas(240-353) was increased by more than 80% compared to the Pseudo-UTP-modified reference RNA constructs comprising the full length Gnas 3’UTR (1 vs. 1.872704502).
[0429] Table 3: Normalized expression data of RNA constructs
[0430]
[0431] Additionally, the dsRNA content of all RNA constructs was measured with standard protocols (see Table 4).
[0432] Table 4: dsRNA content of RNA constructs
[0433]
[0434] Unexpectedly, modified as well as unmodified RNA comprising a minimized 3’UTR Gnas(240-353) sequence element showed a lower dsRNA content compared to the corresponding reference RNA constructs comprising the full length 3’UTR Gnas(1 -353) sequence. A lower dsRNA content is advantageous in the context of a pharmaceutical application, e.g. when administered as a medicament, as dsRNA can induce unwanted side-effects in vivo.Example 3: Gnas-min improves manufacturability and / or expression of RNA constructs
[0435] The goal of this experiment was to analyze whether a minimized 3’UTR Gnas (240-353) sequence element (Gnas-min) can improve the manufacturability and / or increase the expression of RNA constructs comprising coding sequences encoding for large proteins (e.g. Cas9).
[0436] 3.1 : Preparation of DNA templates for RNA in vitro transcription
[0437] DNA sequences encoding a large therapeutic protein (in this Example: Cas9) were prepared and used for subsequent RNA in vitro transcription reactions. DNA sequences were prepared by modifying the wild type or reference encoding DNA sequences by introducing a G / C optimized coding sequence for stabilization and expression optimization.
[0438] Sequences were introduced into a pUC derived DNA vector to comprise a 5’UTR and minimized 3’UTR Gnas(240-353) sequence element or full length 3’UTR Gnas(1-353) and a Poly(A)sequence. The obtained plasmid DNA templates were transformed and propagated in bacteria using common protocols known in the art. Eventually, the plasmid DNA templates were extracted, purified, and linearized. The herein used RNA constructs are provided in Table 5.
[0439] Table 5: RNA constructs usedin the example 3
[0440]
[0441] 3.2. RNA in vitro transcription from plasmid DNA templates
[0442] Linearized DNA templates were used for DNA dependent RNA in vitro transcription (IVT) using T7 RNA polymerase in the presence of a sequence optimized nucleotide mixture (ATP / GTP / CTP / UTP) and cap analog (for cap1 : m7G(5’)ppp(5’)(2’OMeA)pG; TriLink) under suitable buffer conditions. Other constructs were produced in the presence of a nucleotide mixture comprising (ATP / GTP / CTP / N1 -methylpseudouridine (1 mip)) and a cap analog. Other constructs were produced in the presence of a nucleotide mixture comprising (ATP / GTP / CTP / Pseudo-UTP (ip)) or (ATP / GTP / 5- methyl-CTP(5mC) / Pseudo-UTP (ip)) and a cap analog. After RNA in vitro transcription, the obtained RNA IVT reaction was subjected to purification steps comprising RP-HPLC and / or TFF.
[0443] 3.3. Improved producibilitv of RNA constructs comprising a Gnas-min
[0444] The goal of this experiment was to evaluate whether the manufacturing of RNA can be improved for RNA constructs comprising a minimized 3’UTR Gnas(240-353) sequence element (Gnas-min).It was observed that, during the production of RNA constructs comprising the full length 3’UTR Gnas(1-353) sequence (R6746; SEQ ID: 659), an additional RNA species emerged alongside the product (Figure 2A). Accordingly, RNA with reduced RNA integrity was produced. This by-product disappeared through a step of oligo(dT) purification (see Figure 2B), which indicates that this impurity contained RNA lacking a Poly(A) sequence, and that this impurity was a product of incomplete synthesis of the RNA construct. Surprisingly, by using a minimized 3’UTR Gnas(240-353) sequence element instead of the full length 3’UTR Gnas(1-353) sequence, the production efficiency of the respective RNA construct comprising Gnas-min could be significantly improved as e.g. less additional RNA species were observed and a higher RNA integrity was obtained.
[0445] 3.4 Improved in vitro expression of modified RNA constructs comprising a Gnas-min
[0446] The goal of this experiment was to analyze whether 1 mi modification of RNA constructs with a minimized 3’UTR Gnas(240-353) sequence element could improve the expression of Cas9.
[0447] Table 6: RNA constructs used in example 3.4
[0448]
[0449] Primary Human Hepatocytes cells were seeded in 96-well plates in a compatible complete cell medium (i.e., 10O I of plating followed by maintenance medium according to manufacturer instruction, Gibco 100 pl each). Cells were maintained at 37°C, 5% CO2 for 24 hours. The day of transfection, 500ng of RNA (see Table 6) were complexed with lipofectamine Messenger Max at a ratio of 1 :4. 10pl of lipocomplexed RNA was added to corresponding 96-well-plates and further incubated for 24 hours at 37°C, 5% CO2 before performing western blotting. For western blot analysis, cells were washed with PBS1X and lysed with 1X Licor Protein loading buffer containing 1% benzonase (Li-COR). Ten to fifteen minutes after incubation, lysates were centrifuged at maximal speed. Supernatants were applied to SDS-PAGE (4-15% Criterion gels) and transferred to nitrocellulose membranes. Membranes were blocked (TBS 1X, 5% skim milk power), and incubated for one hour with the following primary antibodies in dilution buffer: polyclonal rabbit antibodies against spCas9 (1 / 1000; #632606; Clontech / Takara) and mouse anti-b-actin (1 / 20,000; ab6276, Abeam). Then, membranes were then washed 3 times with 0.1 % Tween-20 in TBS1 X for 5 minutes under mild shaking (80rpm). Subsequently, secondary antibodies, i.e. infrared dye® 800CW goat anti-rabbit antibodies (1 / 10,000; LI-COR), and infrared dye® 680RD goat anti-mouse monoclonal antibodies were incubated one hour at room temperature. After washing step, detection was performed as described above before scanning using Odyssey® CLx Imaging system (LI- COR). Relative quantification (800 / 700) was obtained using Image StudioTM Lite Software.
[0450] The RNA constructs modified with 1mi showed improved expression of the Cas9 protein (see Figure 3) compared to RNA constructs modified with qj.
[0451] 3.5 Immunostimulatory properties of modified and unmodified RNA constructs comprising a Gnas-min The goal of this experiment was to compare the induction of IFNa upon administration of RNA constructs comprising a minimized 3’UTR Gnas(240-353) with reference RNA constructs comprising the full length 3’UTR Gnas(1-353).Table 7 RNA constructs used in example 3.5
[0452]
[0453] PBMCs from two donors (200,000 cells / 150 pl) were seeded into 96 well-plates and stimulated with lipo-complexed RNA for 20 hours at two doses: low (100ng) and high (500ng) amounts. IFNa levels in the supernatants were measured by using BD® Cytometric Bead Array (CBA) according to manufacturer recommendations.
[0454] Surprisingly, the RNA constructs with a minimized 3’UTR Gnas(240-353) sequence element induced less IFNa compared to the reference RNA construct comprising the full length 3’UTR Gnas(1-350) sequence (see Figure 4). Surprisingly, * modified RNA constructs comprising a minimized 3’UTR Gnas(240-353) sequence induced very low to zero levels of IFNa after transfection.
[0455] In the context of a gene editing therapy, no immunostimulatory effects of the administered RNA is desired. The RNA construct with a minimized 3’UTR Gnas(240-353) sequence element and additional uracil modifications show a suitable profile for such a therapy.
[0456] 3.6 Analysis of optimal polv(A) lengths in RNA constructs comprising a Gnas-min
[0457] The goal of this experiment was to analyse the impact of the poly(A) tail length for the expression profile of RNA constructs comprising a minimized 3’UTR Gnas(240-353) sequence element.
[0458] Table 8: RNA constructs used in example 3.6
[0459]
[0460] Human embryonic kidney 293T (HEK293T) cells were seeded in 96-well-plates at a density of 40.000 cells / well in 200pl for 24hr. Two micrograms of each mRNA were complexed with lipofectamine Messenger Max at a ratio 1:1.5 (w / v). Serial dilution was then performed down to 12.5ng. After 24 hours of incubation, cells were lysed with RIPA buffer containing benzonase 1 %. Quantification of spCas9 in lysates was measured by using a commercially available spCas9 ELISA assay (XpressBio).
[0461] The RNA constructs with a poly(A) sequence length of 60, 80, 100, 120 and 140 adenosines showed high expression compared to the RNA constructs with a shorter poly(A) sequence (see Figure 5A). The RNA constructs with a poly(A) sequence length of 80, 100 and 120 adenosines showed the highest expression levels of Cas9 (Figure SB).
Claims
Claims1. An artificial RNA comprisingat least one coding sequence; andat least one 3’ untranslated region (3’ UTR) comprising at least one minimized Gnas 3’ UTR sequence element (Gnas-min),wherein Gnas-min consists of a section of 70 to 150 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5.
2. The artificial RNA of claim 1 , wherein Gnas-min consists of a section of 80 to 150, 90 to 140, 100 to 130, 110 to 120, consecutive nucleotides, wherein the section is taken from a nucleic acid sequence identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5.
3. The artificial RNA of claim 2, wherein Gnas-min consists of a section of 110 to 120 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5.
4. The artificial RNA of claims 1 to 3, wherein Gnas-min consists of a section of 70, 71 , 72, 63, 74, 75, 86, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, or 150 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5.
5. The artificial RNA of claims 1 to 4, wherein the respective section is taken from the 3’ terminal end of the nucleic add sequence identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5.
6. The artificial RNA of any one of the preceding claims, wherein Gnas-min comprises or consists of a nucleotide sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3, 5-7, 53-607.
7. The artificial RNA of claim 6, wherein Gnas-min comprises or consists of a nucleotide sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1 -3, 5-7, 53- 131.
8. The artificial RNA of claim 6, wherein Gnas-min comprises or consists of a nucleotide sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1 -3, 82-91 , 213-607.
9. The artificial RNA of claims 6 to 8, wherein Gnas-min comprises or consists of a nucleotide sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3,82-91.
10. The artificial RNA of any one of the preceding claims, wherein Gnas-min comprises or consists of a nucleotide sequence identical to, or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 1-3.
11. The artificial RNA of claim 10, wherein Gnas-min consists of a nucleotide sequence SEQ ID NO: 2.
12. The artificial RNA of any one of the preceding claims, comprising at least one 5’ untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element13. The artificial RNA of any one of the preceding claims, wherein the 3’ UTR sequence element and / or the 5’ UTR sequence element is heterologous to said coding sequence.
14. The artificial RNA of claim 12 or 13, wherein the at least one 5’ UTR sequence element comprises a nucleic acid sequence derived or selected from a 5-UTR from HSD17B4, AIG1 , alpha-globin (HBA1 , HBA2), ASAH1 , ATP5A1 , COX6C, DPYSL2, HHV5, MDR, MP68, NDUFA4, NOSIP, RPL31, RPL32, RPL35A, SLC7A3, synthetic origin, TUBB4B, UBQLN2, or from a homolog, a fragment or variant of any one of these.
15. The artificial RNA of claim 14, wherein the at least one 5-UTR sequence element comprises or consist of a nucleic add sequence identical to, or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 24-52, or a fragment or a variant of any of these.
16. The artificial RNA of claims 12 to 15, wherein the at least one 5’-UTR element comprises or consists of a nucleic add sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 24-26, or a fragment or a variant of any of these.
17. The artificial RNA of claims 12 to 16, wherein the at least one 5-UTR element comprises or consists of a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 25, or a fragment or variant thereof.
18. The artificial RNA of any one of the preceding claims, comprisingat least one 5’ untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element; at least one coding sequence;at least one 3’ untranslated region (3’ UTR) comprising at least one minimized Gnas 3’ UTR sequence element (Gnas-min);wherein Gnas-min consists of a nucleotide sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2, and wherein the at least one 5’-UTR element comprises or consists of a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 25.
19. The artificial RNA of any one of the preceding claims, wherein the artificial RNA comprises at least one modified nucleotide.20 The artificial RNA of any one of the preceding claims, wherein the artificial RNA comprises at least one modified uridine nucleotide.
21. The artificial RNA of claim 19 or 20, wherein the at least one modified nucleotide is selected from pseudouridine, N1 -methylpseudouridine, N1 -ethylpseudouridine, 2-thiouridine, 4’-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyH-deaza-pseudouridine, 2-thio-1-methyl-pseudouiidine, 2- thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio- pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine and 2'-O-methyl uridine.
22. The artificial RNA of claim 21 , wherein the at least one modified nucleotide is selected from N 1 - methylpseudouridine or pseudouridine, preferably N1 -methylpseudouridine23. The artificial RNA of claims 19 to 22, wherein 100% of the uracil in the nucleic acid sequence of the artificial RNA comprise a chemical modification, preferably a chemical modification in the 5-position of the uracil.
24. The artificial RNA of claim 23, wherein 100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with pseudouridine or N1-methylpseudouridine, preferably with N1-methylpseudouridine.
25. The artificial RNA of claim 24, wherein 100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with N1 -methylpseudouridine.
26. The artificial RNA of any one of the preceding claims, comprising at least one poly(A) sequence.
27. The artificial RNA of claim 26, wherein the at least one poly(A) sequence comprises 20 to 500 adenosine nucleotides, 40 to 250 adenosine nucleotides, 60 to 200 adenosine nucleotides, 60 to 150 adenosine nucleotides, preferably 60 to 150 adenosine nucleotides.
28. The artificial RNA of claim 26 or 27, wherein the at least one poly(A) sequence comprises about 80, about 100, or about 120 adenosine nucleotides, preferably wherein the at least one poly(A) sequence comprises 100 adenosine nucleotides29. The artificial RNA of claims 26 to 28, wherein the at least one poly(A) sequence is located directly at the 3’ terminus of the artificial RNA, thereby representing the 3’ terminal sequence end of the artificial RNA 30. The artificial RNA of any one of the preceding claims, comprising at least one histone stem-loop (hsl) sequence.
31. The artificial RNA of claim 30, wherein the at least one hSL sequence comprises or consists of a nucleic acid sequence identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 16, or a fragment or variant thereof.
32. The artificial RNA of claim 30 or 31 , wherein the at least one hSL sequence is located between the Gnas-min sequence element and the poly(A) sequence.
33. The artificial RNA of any one of the preceding claims, comprising a 5’-cap structure.
34. The artificial RNA of claim 33, wherein the 5’-cap structure is selected from m7G, capO, cap1 , cap2, or a modified version of any of these.
35. The artificial RNA of claim 33 or 34, wherein the 5’-cap structure is a cap1 structure.
36. The artificial RNA of claim 35, wherein the cap1 structure is selected from m7G(5’)ppp(5’)(2’OMeA)pG, m7(3’OMeG)(5’)ppp(5')(2’OMeA)pG, or m7(3’OMeG)(5’)ppp(‘5)m6(2’OMeA)pG, preferably wherein the cap1 structure is m7G(5’)ppp(5’)(2’OMeA)pG.
37. The artificial RNA of any one of the preceding claims, wherein the at least one coding sequence encodes at least one therapeutic peptide or protein.
38. The artificial RNA of claim 37, wherein the at least one therapeutic peptide or protein is selected from a CRISPR-associated endonuclease, an antibody, an intrabody, a receptor, a receptor agonist, a receptor antagonist, a binding protein, a chaperone, a transporter protein, an ion channel, a membrane protein, a secreted protein, a transcription factor, an enzyme, a peptide or protein hormone, a growth factor, a structural protein, a cytoplasmic protein, a cytoskeletal protein, a viral antigen or epitope, a bacterial antigen or epitope, a protozoan antigen or epitope, an allergen, an autoantigen, a tumor antigen or epitope, or fragments, variants, or combinations of any of these.
39. The artificial RNA of claim 37 or 38, wherein the at least one therapeutic peptide or protein is selected from a CRISPR-associated endonuclease, or a fragment or variant thereof.
40. The artificial RNA of claim 39, wherein the CRISPR-associated endonuclease is selected from Cas9, Cpf1 (Cas12), C2c1, C2c3, Cas13, CasX, orCasY.
41. The artificial RNA of claim 40, wherein the CRISPR-associated endonuclease is Cas9.
42. The artificial RNA of claims 39 to 41 , wherein the CRISPR-associated endonuclease comprises or consists of an amino acid sequence identical to, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 617 or 618, or a fragment or variant of any of these.
43. The artificial RNA of claim 42, wherein the CRISPR-associated endonuclease comprises or consists of an amino acid sequence identical to, or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 617, or a fragment or variant thereof.
44. The artificial RNA of any one of the preceding claims, wherein the at least one coding sequence is a codon modified coding sequence.
45. The artificial RNA of claim 44, wherein the codon modified coding sequence is selected from a C maximized coding sequence, a CAI maximized coding sequence, a human codon usage adapted coding sequence, a G / C content modified coding sequence, a G / C optimized coding sequence, or any combination thereof.
46. The artificial RNA of claim 45, wherein the at least one coding sequence has a G / C content of at least about 59%, 60%, 61%.
47. The artificial RNA of any one of the preceding claims, wherein the at least one coding sequence encodes a CRISPR-associated endonuclease and comprises or consists of a nucleic acid sequence identical to, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 611- 616, or a fragment or variant of any of these.
48. The artificial RNA of claim 47, wherein the at least one coding sequence encodes a Cas9 endonuclease and comprises or consists of a nucleic acid sequence identical to, or at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 612 or 615, or a fragment or variant thereof.
49. The artificial RNA of any one of the preceding claims, wherein the at least one coding sequence has a length of at least 3500 nucleotides, 4000 nucleotides, or 4500 nucleotides.
50. The artificial RNA of any one of the preceding claims, comprising at least one miRNA binding site, a Kozak sequence and / or at least one poly(C)sequence.
51. The artificial RNA of any one of the preceding claims, wherein the artificial RNA is an mRNA, a circRNA, a replicon RNA, a self-replicating RNA, or viral RNA, preferably wherein the artificial RNA is an mRNA.
52. The artificial RNA of any one of the preceding claims, comprising in 5’ to 3’ directiona) a Cap structure, preferably as defined in any one of claims 33 to 36;b) at least one 5’ untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element as defined in any one of claims 12 to 17;c) at least one coding sequence, preferably as defined in any one of claims 37 to 49;d) at least one 3’ untranslated region (3’ UTR) comprising a minimized Gnas 3’ UTR sequence element (Gnas-min) as defined in any one of claims 1 to 11;e) optionally, at least on hsl as defined in any one of claims 30 to 32;f) at least one poly(A) sequence, preferably as defined in any one of claims 26 to 29;wherein the artificial RNA preferably comprises at least one modified nucleotide as defined in any one of claims 19 to 25.
53. The artificial RNA of any one of the preceding claims, comprising in 5’ to 3’ directiona) a Cap1 structure, preferably as defined in claim 36;b) at least one 5' untranslated region (5’ UTR) comprising at least one 5’ UTR sequence element from HSD17B4 comprising or consisting of a nucleic acid sequence SEQ ID NO: 25;c) at least one coding sequence as defined in any one of claims 37 to 49, preferably comprising or consisting of a nucleic acid sequence encoding a CRISPR-associated endonuclease, more preferably wherein the CRISPR-associated endonuclease comprises or consists of an amino acid sequence being identical to, or at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 617 or 618, or a fragment or variant thereof;d) at least one 3’ untranslated region (3’ UTR) comprising a minimized Gnas 3’ UTR sequence, wherein Gnas-min consists a nucleic acid sequence SEQ ID NO: 2;e) optionally, at least on hsl comprising or consisting of a nucleic acid sequence identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 16;f) at least one poly(A) sequence having about 100 A nucleotides located directly at the 3’ terminus of the artificial RNA, thereby representing the 3' terminal sequence end of the artificial RNA; wherein 100% of the uracil in the nucleic acid sequence of the artificial RNA are substituted with N1- methylpseudouridine.
54. The artificial RNA of any one of the preceding claims, comprisinga 5’ portion comprising or consisting of a nucleic acid sequence being identical to, or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 9-11, preferably SEQID NO: 10;a central portion comprising a cds preferably as defined in any one of claims 37 to 49, more preferably comprising or consisting of a nucleic acid sequence encoding a CRISPR-associated endonuclease;a 3' portion comprising Gnas-min, the 3’ sequence portion comprising or consisting of a nucleic acid sequence being identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 12-14, preferably SEQ ID NO: 13.
55. The artificial RNA of any one of the preceding claims, wherein the artificial RNA comprises or consists of a nucleic add sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 608-610, 619-654, 662-667, or a fragment or variant of any of these sequences.
56. The artificial RNA of claim 55, wherein the artificial RNA comprises or consists of an N1 -methylpseudouridine modified nudeic add sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 609, 631 -642, 662-667.
57. The artificial RNA of claim 55 or 56, wherein the artificial RNA comprises or consists of an N1 - methylpseudouridine nucleic acid sequence which is identical to, or at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 609.
58. The artificial RNA of any one of the preceding claims, wherein the artificial RNA comprises or consists of an N1 -methylpseudouridine modified nucleic acid sequence identical to SEQ ID NO: 609.
59. The artificial RNA of any one of the preceding claims, wherein the RNA integrity of the artificial RNA is increased during or after manufacturing compared to the RNA integrity of a reference RNA that comprises a full length Gnas 3’ UTR sequence and / or wherein the dsRNA content of the artificial RNA is decreased during or after manufacturing compared to the dsRNA content of a reference RNA that comprises a full length GNAS 3' UTR sequence.
60. The artificial RNA of any one of the preceding claims, wherein the translation efficiency of the artificial RNA is increased compared to the translation efficiency of a reference RNA that comprises a full length Gnas 3’ UTR sequence, and / or wherein the translation efficiency of the artificial RNA that contains at least one modified nucleotide, preferably N1 -methylpseudouridine, is increased compared to the translation efficiency of a reference RNA that comprises a full length Gnas 3’ UTR sequence and contains at least one modified nucleotide, preferably N1 -methylpseudouridine.
61. A pharmaceutical composition comprising at least one artificial RNA as defined in any one of claims 1 to 60.
62. The pharmaceutical composition of claim 61 , wherein the at least one artificial RNA is formulated with at least one cationic or polycationic compound.
63. The pharmaceutical composition of claim 62, wherein the at least one cationic or polycationic compound is selected from a cationic or polycationic polymer, a cationic or polycationic polysaccharide, a cationic orpolycationic lipid, a cationic or polycationic protein, a cationic or polycationic peptide, or any combinations thereof.
64. The pharmaceutical composition of claims 61 to 63, wherein the at least one artificial RNA is formulated in a lipid-based carrier.
65. The pharmaceutical composition of claim 64, wherein the lipid-based carrier is selected from a lipid nanoparticle (LNP), a liposome, a lipoplex, a solid lipid nanoparticle, a lipo-polyplex, and / or a nanoliposome, preferably wherein the lipid-based carrier is a lipid nanoparticle (LNP).
66. The pharmaceutical composition of claim 64 or 65, wherein the lipid-based carrier, preferably the LNP, comprise at least one or more lipids selected from at least one aggregation-reducing lipid, at least one cationic lipid or ionizable lipid, at least one neutral lipid or phospholipid, or at least one steroid or steroid analog, or any combinations thereof.
67. The pharmaceutical composition of claims 64 to 66, wherein the lipid-based carrier, preferably the LNP, comprises(i) at least one cationic lipid or ionizable lipid;(ii) at least one neutral lipids or phospholipids;(iii) at least one steroid or steroid analog; and(iv) at least one aggregation reducing lipid.
68. The pharmaceutical composition of claim 67, wherein the lipid-based carrier, preferably the LNP, comprise (i) to (iv) in a molar ratio of about 20-60% cationic lipid or ionizable lipid, about 5-25% neutral lipid, about 25-55% steroid or steroid analog, and about 0.5-15% aggregation reducing lipid e.g. polymer conjugated lipid.
69. The pharmaceutical composition of claims 61 to 68, wherein the composition comprises (a) at least one artificial RNA encoding a CRISPR-associated endonuclease, and, optionally, (b) at least one guide RNA (gRNA) or a nucleic acid encoding the same, said gRNA being capable of targeting the CRISPR-associated endonuclease to a target DNA sequence of interest, or a regulatory element operably linked thereto.
70. The pharmaceutical composition of claim 69, wherein (a) the at least one artificial RNA encoding the at least one CRISPR-associated endonuclease, and (b) the at least one guide RNA (gRNA), are co-formulated in one or more cationic or polycationic compound, preferably in a lipid-based carrier as defined in any one of claims 64 to 68.
71. The pharmaceutical composition of claim 69, wherein (a) the at least one artificial RNA encoding the at least one CRISPR-associated endonuclease, and (b) the at least one guide RNA (gRNA), are formulated separately in one or more cationic or polycationic compound, preferably in a lipid-based carrier as defined in any one of claims 64 to 68.
72. A kit or kit of parts, comprising the artificial RNA of any one of claims 1 to 60 and / or the pharmaceutical composition of any one of claims 61 to 71 , and, optionally, a liquid vehicle and / or technical instructions with information on the administration and dosage of the artificial RNA or the pharmaceutical composition.
73. The kit or kit of parts of claim 72, comprisingat least one artificial RNA encoding a CRISPR-associated endonuclease, or a pharmaceutical composition comprising said artificial RNA encoding; andat least one guide RNA (gRNA) or a nucleic acid encoding the same, said gRNA being capable of targeting the CRISPR-associated protein to a target DNA sequence of interest, or a regulatory element operably linked thereto.
74. The artificial RNA of any one of claims 1 to 60, the pharmaceutical composition of any one of claims 61 to 71 , or the kit of claim 72 or 73, for use as a medicament.
75. The artificial RNA of any one of claims 1 to 60, the pharmaceutical composition of any one of claims 61 to 71 , or the kit of claim 72 or 73, for use in gene therapy76. The artificial RNA of any one of claims 53 to 58, the pharmaceutical composition of any one of claims 73 to 75, or the kit of claim 73, for use in gene therapy77. The artificial RNA of any one of claims 53 to 58, the pharmaceutical composition of any one of claims 73 to 75, or the kit of claim 73, for use in a method of modulating the expression of a gene of interest, comprising administering to a patient in need thereof (a) said artificial RNA, said pharmaceutical composition or said kit and (b) a guide RNA (gRNA) or a nucleic acid encoding the same, said sgRNA being capable of targeting the CRISPR-associated protein to a gene of interest, or a regulatory element operably linked thereto.
78. The artificial RNA of any one of claims 53 to 58, the pharmaceutical composition of any one of claims 73 to 75, or the kit of claim 73, for use as a medicament or for use in gene therapy in a disease, disorder or condition amenable by knocking in, knocking out or manipulating a gene of interest, or by modulating the expression of a gene of interest.
79. The artificial RNA, the pharmaceutical composition, or kit for the use as a medicament according to claim 78, wherein the disease, disorder or condition is selected from genetic diseases, cancer, autoimmune diseases, inflammatory diseases, and infectious diseases.
80. A method of treating or preventing a disease, disorder, or condition, wherein the method comprises administering to a subject in need thereof an effective amount of the artificial RNA of any one of claims 1 to 60, the pharmaceutical composition of any one of claims 61 to 71 , or the kit of claim 72 or 73.
81. The method of treating or preventing a disease, disorder, or condition of claim 80, further characterized by any one of the features of claims 74 to 79.
82. Use of a minimized Gnas UTR element (Gnas-min) for improving the translation efficiency of an RNA, wherein Gnas-min consists of a section of 70 to 140 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, wherein Gnas-min is preferably further characterized by any one of the features of claims 2 to 11.
83. The Use of claim 82, wherein Gnas-min comprises at least one modified nucleotide, preferably pseudouridine or N1 -methylpseudouridine, more preferably N1 -methylpseudouridine.
84. The Use of claim 82 or 83, wherein the RNA comprises at least one 5’ UTR sequence element from HSD17B4 comprising or consisting of a nucleic acid sequence identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 24-26, or a fragment or variant thereof.
85. Use of a minimized Gnas UTR element (Gnas-min) for improving the manufacturability of an RNA, wherein Gnas-min consists of a section of 70 to 140 consecutive nucleotides, wherein the section is taken from a nucleic add sequence that is identical to or at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, wherein Gnas-min is preferably further characterized by any one of the features of claims 2 to 11.
86. The Use of claim 85, wherein the encoded therapeutic peptide or protein is encoded by a coding sequence that has a length of at least 3500 nudeotides, 4000 nudeotides, 4500 nucleotides.
87. The Use of claim 85 or 86, wherein the RNA comprises at least one 5’ UTR sequence element from HSD17B4 comprising or consisting of a nucleic acid sequence being identical to, or at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 24-26, or a fragment or variant thereof.
88. A method for produdng an RNA comprising at least one coding sequence, said method comprising(A) providing a DNA template comprising at least on coding sequence and at least one 3’ UTR comprising at least one GNAS-min, wherein Gnas-min consists of a section of 70 to 140 consecutive nucleotides, wherein the section is taken from a nucleic acid sequence that is identical to or at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, wherein Gnas-min is preferably further characterized by any one of the features of claims 2 to 11 ; and (B) obtaining a preparation comprising the artificial RNA by at least one step of RNA in vitro transcription; (C) purifying the obtained preparation by at least one step of purification;(D) formulating the purified artificial RNA in a lipid-based carrier by at least one step of formulation.
